IMAX (IMAX) 10-Q 20 Apr 17 2017 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information	3 Months Ended
	Mar. 31, 2017shares
Document and Entity Information [Abstract]
Entity Registrant Name	IMAX Corporation
Entity Central Index Key	921,582
Document Type	10-Q
Document Period End Date	Mar. 31, 2017
Amendment Flag	false
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q1
Current Fiscal Year End Date	--12-31
Entity Well Known Seasoned Issuer	Yes
Entity Voluntary Filers	Yes
Entity Current Reporting Status	Yes
Entity Filer Category	Large Accelerated Filer
Entity Common Stock Shares Outstanding	66,573,078
Trading Symbol	IMAX

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Assets
Cash and cash equivalents	$ 190,481	$ 204,759
Accounts receivable, net of allowance for doubtful accounts of $1,282 (December 31, 2016 - $1,250)	96,113	96,349
Financing receivables	120,490	122,125
Inventories	45,433	42,121
Prepaid expenses	8,047	6,626
Film assets	13,413	16,522
Property, plant and equipment	248,228	245,415
Other assets	19,660	33,195
Deferred income taxes	29,491	20,779
Other intangible assets	31,106	30,416
Goodwill	39,027	39,027
Total assets	841,489	857,334
Liabilities
Total bank indebtedness	26,826	27,316
Accounts payable	13,935	19,990
Accrued and other liabilities	75,424	93,208
Deferred revenue	100,901	90,266
Total liabilities	217,086	230,780
Commitments and contingencies
Non-controlling interests
Non-controlling interests	2,555	4,980
Shareholders' equity
Capital stock common shares - no par value. Authorized - unlimited number. 66,596,784 issued and 66,573,078 outstanding (December 31, 2016 - 66,224,467 issued and 66,159,902 outstanding)	455,838	439,213
Less: Treasury stock, 23,706 shares at cost (December 31, 2016 - 64,565)	(779)	(1,939)
Other equity	165,670	177,304
Accumulated deficit	(55,605)	(47,366)
Accumulated other comprehensive loss	(4,447)	(5,200)
Total shareholders' equity attributable to common shareholders	560,677	562,012
Non-controlling interests	61,171	59,562
Total shareholders' equity	621,848	621,574
Total liabilities and shareholders' equity	$ 841,489	$ 857,334

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
Assets
Allowance for doubtful accounts	$ 1,282	$ 1,250
Shareholders' equity
Common stock, shares issued	66,596,784	66,224,467
Common stock, shares outstanding	66,573,078	66,159,902
Number of treasury shares held in trust for future settlement of share based awards	23,706	64,565

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Revenues
Equipment and product sales	$ 11,544	$ 23,740
Services	38,844	44,273
Rentals	15,857	21,779
Finance income	2,412	2,336
Revenues, total	68,657	92,128
Costs and expenses applicable to revenues
Equipment and product sales	7,464	17,791
Services	19,814	17,596
Rentals	5,608	4,565
Cost and expenses applicable to revenues, total	32,886	39,952
Gross margin	35,771	52,176
Selling, general and administrative expenses (including share-based compensation expense of $5.3 million for the three months ended March 31, 2017 (2016 - expense of $5.9 million))	30,941	28,919
Research and development	4,334	3,708
Amortization of intangibles	602	491
Receivable provisions, net of recoveries	185	126
(Loss) income from operations	(291)	18,932
Interest income	228	467
Interest expense	(455)	(398)
(Loss) income from operations before income taxes	(518)	19,001
Provision for income taxes	(114)	(4,608)
Loss from equity-accounted investments, net of tax	(255)	(441)
Net (loss) income	(887)	13,952
Less: Net loss (income) attributable to non-controlling interests	962	(2,650)
Net income attributable to common shareholders	$ 75	$ 11,302
Net income per share attributable to common shareholders - basic and diluted:
Net income per share - basic	$ 0	$ 0.16
Net income per share - diluted	$ 0	$ 0.16

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Operations (Unaudited) (Parenthetical) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Condensed Consolidated Statements of Operations [Abstract]
Share-based compensation costs	$ 5.3	$ 5.9

Condensed Consolidated Stateme6

Condensed Consolidated Statements of Comprehensive Income (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Net (loss) income	$ (887)	$ 13,952
Unrealized net gain from cash flow hedging instruments	313	2,207
Realization of cash flow hedging net loss upon settlement	285	1,277
Foreign currency translation adjustments	458	422
Amortization of postretirement benefit plan actuarial loss	0	17
Other comprehensive income, before tax	1,056	3,923
Income tax expense related to other comprehensive income	(157)	(911)
Other comprehensive income, net of tax	899	3,012
Comprehensive income	12	16,964
Less: Comprehensive loss (income) attributable to non-controlling interests	816	(1,951)
Comprehensive income attributable to common shareholders	$ 828	$ 15,013

Condensed Consolidated Stateme7

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Operating Activities
Net (loss) income	$ (887)	$ 13,952
Adjustments to reconcile net (loss) income to cash from operations:
Depreciation and amortization	12,088	10,438
Write-downs, net of recoveries	4,010	648
Change in deferred income taxes	(958)	(185)
Stock and other non-cash compensation	5,660	6,002
Unrealized foreign currency exchange gain	(171)	(557)
Loss from equity-accounted investments	156	818
Loss (gain) on non-cash contribution to equity-accounted investees	99	(377)
Investment in film assets	(3,334)	(3,919)
Changes in other non-cash operating assets and liabilities	(17,280)	(21,783)
Net cash (used in) provided by operating activities	(617)	5,037
Investing Activities
Purchase of property, plant and equipment	(4,068)	(4,585)
Investment in joint revenue sharing equipment	(7,547)	(3,988)
Investment in new business ventures	(1,000)	0
Acquisition of other intangible assets	(1,591)	(770)
Net cash used in investing activities	(14,206)	(9,343)
Financing Activities
Repayment of bank indebtedness	(500)	(500)
Settlement of restricted share units and options	(11,158)	(5,849)
Common shares issued - stock options exercised	13,082	740
Treasury stock purchased for future settlement of restricted share units	(779)	0
Taxes withheld and paid on employee stock awards vested	(146)	(73)
Repurchase of common shares	0	(44,618)
Taxes paid on secondary sale and repatriation dividend	0	(2,991)
Net cash provided by (used in) provided by financing activities	499	(53,291)
Effects of exchange rate changes on cash	46	(100)
Decrease in cash and cash equivalents during period	(14,278)	(57,697)
Cash and cash equivalents, beginning of period	204,759	317,449
Cash and cash equivalents, end of period	$ 190,481	$ 259,752

Basis of Presentation

Basis of Presentation	3 Months Ended
	Mar. 31, 2017
Basis of Presentation and Condensed Consolidated Statements of Operations Supplemental Information [Abstract]
Basis of Presentation	1. Basis of Presentation IMAX Corporation, together with its consolidated subsidiaries (the “Company”), prepares its financial statements in accordance with United States Generally Accepted Accounting Principles (“U.S. GAAP”). The condensed consolidated financial statements include the accounts of the Company together with its consolidated subsidiaries, except for subsidiaries which the Company has identified as variable interest entities (“VIEs”) where the Company is not the primary beneficiary. The nature of the Company’s business is such that the results of operations for the interim periods presented are not necessarily indicative of results to be expected for the fiscal year. In the opinion of management, the information contained herein reflects all normal and recurring adjustments necessary to make the results of operations for the interim periods a fair statement of such operations. The Company has evaluated its various variable interests to determine whether they are VIEs as required by the Consolidation Topic of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC” or “Codification”). The Company has nine film production companies that are VIEs. For four of the Company’s film production companies, the Company has determined that it is the primary beneficiary of these entities as the Company has the power to direct the activities of the respective VIE that most significantly impact the respective VIE’s economic performance and has the obligation to absorb losses of the VIE that could potentially be significant to the respective VIE or the right to receive benefits from the respective VIE that could potentially be significant to the respective VIE. These consolidated production companies have total assets of $ 5.8 million (December 31, 2016 — $ 10.3 million) and total liabilities of $ 6.5 million as at March 31, 2017 (December 31, 2016 — $ 6.4 million). The majority of these consolidated assets are held by the IMAX Original Film Fund (the “Film Fund”) as described in note 16(b). For the other five film production companies which are VIEs, the Company did not consolidate these film entities since it does not have the power to direct activities and does not absorb the majority of the expected losses or expected residual returns. The Company equity accounts for these entities. As at March 31, 2017 , these five VIEs have total assets of $ 0.4 million (December 31, 2016 — $ 0.4 million) and total liabilities of $ 0.4 million (December 31, 2016 — $ 0.4 million). Earnings of the investees included in the Company’s condensed consolidated statements of operations amounted to $nil for the three months ended March 31, 2017 ( 2016 — $nil). The carrying value of these investments in VIEs that are not consolidated is $nil at March 31, 2017 (December 31, 2016 — $nil). A loss in value of an investment other than a temporary decline is recognized as a charge to the condensed consolidated statements of operations. The Company’s exposure, which is determined based on the level of funding contributed by the Company and the development stage of the respective film, is $nil at March 31, 2017 (December 31, 2016 — $nil). The Company accounts for investments in new business ventures using the guidance of the FASB ASC 323 “Investments – Equity Method and Joint Ventures” (“ASC 323”) or ASC 320 “Investments in Debt and Equity Securities” (“ASC 320”), as appropriate. All intercompany accounts and transactions, including all unrealized intercompany profits on transactions with equity-accounted investees, have been eliminated. The year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. These interim financial statements should be read in conjunction with the consolidated financial statements included in the Company’s 2016 Annual Report on Form 10-K for the year ended December 31, 2016 (“the 2016 Form 10-K”) which should be consulted for a summary of the significant accounting policies utilized by the Company. These interim financial statements are prepared following accounting policies consistent with the Company’s financial statements for the year ended December 31, 2016 , except as noted below. Certain prior period information has been revised to reflect the current period information.

New Accounting Standards and Ac

New Accounting Standards and Accounting Changes	3 Months Ended
	Mar. 31, 2017
New Accounting Standards and Accounting Changes [Abstract]
New Accounting Standards and Accounting Changes	2. New Accounting Standards and Accounting Changes Adoption of New Accounting Policies The Company adopted the following standards on January 1, 2017, which are effective for annual periods ending after December 31, 2016, and for annual and interim periods thereafter. In July 2015, the FASB issued ASU No. 2015-11, “Inventory (Topic 330): Simplifying the Measurement of Inventory” (“ASU 2015-11”). The purpose of the amendment is to more closely align the measurement of inventory in U.S. GAAP with the measurement of inventory in International Financial Reporting Standards. Under the ASU inventory is measured at the lower of cost and net realizable value. The clarifications are not intended to result in any changes in practice and to reduce the complexity in guidance on the subsequent measurement of inventory. This standard only applies to inventory being measured using the first-in, first-out or average cost methods of accounting for inventory. The adoption of ASU 2015-11 did not have an impact to the Company’s condensed consolidated financial statements. In March 2016, the FASB issued ASU No. 2016-05, “Derivatives and Hedging (Topic 815): Effect of Derivative Contract Novations on Existing Hedge Accounting Relationships” (“ASU 2016-05”). The amendments in ASU 2016-05 apply to all reporting entities for which there is a change in the counterparty to a derivative instrument that has been designated as a hedging instrument under Topic 815. The amendments clarify that a change in the counterparty to a derivative instrument that has been designated as the hedging instrument under Topic 815 does not, in and of itself, require de-designation of that hedging relationship provided that all other hedge accounting criteria (including those in paragraphs 815-20-35-14 through 35-18) continue to be met. The adoption of this ASU 2016-05 did not have an impact to the Company’s condensed consolidated financial statements. In March 2016, the FASB issued ASU No. 2016-07, “Investments – Equity Method and Joint Ventures (Topic 323): Simplifying the Transition to the Equity Method of Accounting” (“ASU 2016-07”). The purpose of the amendment is to eliminate the requirement that when an investment qualifies for use of the equity method as a result of an increase in the level of ownership interest or degree of influence, an investor must adjust the investment, results of operations, and retained earnings retroactively on a step-by step basis as if the equity method had been in effect during all previous periods that the investment had been held. The adoption of ASU 2016-07 did not have an impact to the Company’s condensed consolidated financial statements. In October 2016, the FASB issued ASU No. 2016-16, “Income Taxes (Topic 740)”. The purpose of ASU 2016-16 is to eliminate the exception for an intra-entity transfer of an asset other than inventory. The amendments require the recognition of the income tax consequences of an intra-entity transfer of an asset, other than inventory, when the transfer occurs. The Company has elected to early adopt ASU 2016-16 during the quarter ended March 31, 2017. The impact from the adoption was reflected in the Company’s condensed consolidated financial statements on a modified retrospective basis resulting in an increase to Accumulated deficit of $8.3 million, a decrease to Other assets of $14.8 million, an increase to Deferred taxes of $7.9 million and an increase to Accrued and other liabilities of $1.4 million. In October 2016, the FASB issued ASU No. 2016-17, “Consolidation (Topic 810)”. The purpose of ASU 2016-17 is to update the requirement of the reporting entity, in determining whether it satisfies the second characteristic of a primary beneficiary, to include all of its direct variable interests in a VIE and, on a proportionate basis, its indirect variable interests in a VIE held through related parties, including related parties that are under common control with the reporting entity. The adoption of ASU 2016-17 did not have an impact to the Company’s condensed consolidated financial statements. Recently Issued FASB Accounting Standard Codification Updates In February 2016, the FASB issued ASU No. 2016-02, “Leases (Topic 842)” (“ASU 2016-02”). The purpose of the amendment is to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. New disclosures will include qualitative and quantitative requirements to provide additional information about the amounts recorded in the financial statements. Lessor accounting will remain largely unchanged from current guidance, however ASU 2016-02 will provide improvements that are intended to align lessor accounting with the lessee model and with updated revenue recognition guidance. For public entities, the amendments in ASU 2016-02 are effective for interim and annual reporting periods beginning after December 15, 2018. While the Company continues to evaluate the effect of the standard on its ongoing financial reporting, it anticipates that the adoption of ASU 2016-02 will result in a change to its financial statement disclosures. In March 2016, the FASB issued ASU No. 2016-08, “Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations” (“ASU 2016-08”). The purpose of ASU 2016-08 is to clarify the implementation of guidance on principal versus agent considerations. In April 2016, the FASB issued ASU No. 2016-10, “Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing” (“ASU 2016-10”). The purpose of ASU 2016-10 is to provide more detailed guidance in the following key areas: identifying performance obligations and licenses of intellectual property. In May 2016, the FASB issued ASU No. 2016-11, to rescind from the FASB Accounting Standards Codification certain SEC paragraphs as a result of two SEC Staff Announcements at the March 3, 2016 meeting. In May 2016, the FASB issued ASU No. 2016-12, “Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients” (“ASU 2016-12”). The purpose of ASU 2016-12 is to clarify certain narrow aspects of Topic 606 such as assessing the collectibility criterion, presentation of sales taxes and other similar taxes collected from customers, noncash consideration, contract modifications at transition, completed contracts at transition, and technical corrections. In December 2016, the FASB issued ASU No. 2016-20, “Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers”. The amendments in ASU 2016-20 represent changes to clarify the accounting standard codification, correct unintended application of guidance, or make minor improvements to the accounting standards codification that are related to Topic 606, Revenue from Contracts with Customers. For public companies, ASU 2016-08, ASU 2016-10, ASU 2016-11, ASU 2016-12 and ASU 2016-20, which are all related to Topic 606, are effective for interim and annual reporting periods beginning after December 15, 2017. The Company has performed an analysis of its contracts to determine those in scope of the standard, has performed detailed analyses of those contracts and identified its performance obligations. The Company is currently in the process of determining contract consideration and is determining the appropriate timing for revenue recognition of those performance obligations. Since many of the Company’s contracts involve variable payments tied to box-office, the Company is currently assessing an appropriate constraint to variable revenue streams in determining contract consideration under the new standard. The Company currently intends to adopt the new standard using the modified retrospective method and has begun the process of gathering historical information on its contracts in preparation for the standard’s expanded disclosure requirements. In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments” (“ASU 2016-13”). The purpose of ASU 2016-13 is to require a financial asset measured on the amortized cost basis to be presented at the net amount expected to be collected. Credit losses relating to available-for-sale debt securities should be recorded through an allowance for credit losses. For public entities, the amendments in ASU 2016-13 are effective for interim and annual reporting periods beginning after December 15, 2019. The Company is currently assessing the impact of ASU 2016-13 on its condensed consolidated financial statements. In January 2017, the FASB issued ASU No. 2017-01, “Business Combinations (Topic 805): Clarifying the Definition of a Business” (“ASU 2017-01”). The purpose of the amendment is to clarify the definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. For public entities, the amendments in ASU 2017-01 are effective for interim and annual reporting periods beginning after December 15, 2017. The adoption of this ASU 2017-01 is not expected to have a material impact to the Company’s condensed consolidated financial statements. In January 2017, the FASB issued ASU No. 2017-04, “Intangibles – Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment” (“ASU 2017-04”). The purpose of the amendment is to simplify how an entity is required to test goodwill for impairment by eliminating Step 2 from the goodwill impairment test. Step 2 measures a goodwill impairment loss by comparing the implied fair value of a reporting unit’s goodwill with the carrying amount of that goodwill. For public entities, the amendments in ASU 2017-04 are effective for interim and annual reporting periods beginning after December 15, 2019. The Company is currently assessing the impact of ASU 2017-04 on its condensed consolidated financial statements. In March 2017, the FASB issued ASU No. 2017-07, “Compensation – Retirement Benefits (Topic 715): Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost” (“ASU 2017-07”). The amendment requires the service cost component of net periodic benefit cost be presented in the same income statement line item as other employee compensation costs arising from services rendered during the period and other components of the net periodic benefit cost be presented separately from the line item that includes the service cost and outside of any subtotal of operating income. For public entities, the amendments in ASU 2017-07 are effective for interim and annual reporting periods beginning after December 15, 2017. The Company is currently assessing the impact of ASU 2017-07 on its condensed consolidated financial statements. The Company considers the applicability and impact of all recently issued FASB accounting standard codification updates. Accounting standards updates that are not noted above were assessed and determined to be not applicable or not significant to the Company’s condensed consolidated financial statements for the period ended March 31, 2017 .

Financing Receivables

Financing Receivables	3 Months Ended
	Mar. 31, 2017
Financing Receivables [Abstract]
Financing Receivables	3. Financing Receivables Financing receivables, consisting of net investment in sales-type leases and receivables from financed sales of theater systems are as follows: March 31, December 31, 2017 2016 Gross minimum lease payments receivable $ 10,119 $ 10,466 Unearned finance income (1,639) (1,710) Minimum lease payments receivable 8,480 8,756 Accumulated allowance for uncollectible amounts (672) (672) Net investment in leases 7,808 8,084 Gross financed sales receivables 151,561 154,301 Unearned finance income (38,385) (39,766) Financed sales receivables 113,176 114,535 Accumulated allowance for uncollectible amounts (494) (494) Net financed sales receivables 112,682 114,041 Total financing receivables $ 120,490 $ 122,125 Net financed sales receivables due within one year $ 22,645 $ 21,980 Net financed sales receivables due after one year $ 90,037 $ 92,061 As at March 31, 2017 , the financed sale receivables had a weighted average effective interest rate of 9.3 % (December 31, 2016 — 9.3 %).

Inventories

Inventories	3 Months Ended
	Mar. 31, 2017
Inventories [Abstract]
Inventories	4. Inventories March 31, December 31, 2017 2016 Raw materials $ 31,565 $ 28,000 Work-in-process 3,994 3,818 Finished goods 9,874 10,303 $ 45,433 $ 42,121 At March 31, 2017 , finished goods inventory for which title had passed to the customer and revenue was deferred amounted to $ 3.3 million (December 31, 2016 — $ 2.3 million). During the three months ended March 31, 2017 , the Company recognized write-downs for excess and obsolete inventory based upon current estimates of net realizable value considering future events and conditions of $nil ( 2016 — $ 0.2 million).

Property Plant and Equipment

Property Plant and Equipment	3 Months Ended
	Mar. 31, 2017
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	5. Property Plant and Equipment As at March 31, 2017 Accumulated Net Book Cost Depreciation Value Equipment leased or held for use Theater system components $ 227,636 $ 93,280 $ 134,356 Camera equipment 5,990 3,879 2,111 233,626 97,159 136,467 Assets under construction 22,175 - 22,175 Other property, plant and equipment Land 8,203 - 8,203 Buildings 70,692 15,439 55,253 Office and production equipment 42,513 23,412 19,101 Leasehold improvements 10,452 3,423 7,029 131,860 42,274 89,586 $ 387,661 $ 139,433 $ 248,228 As at December 31, 2016 Accumulated Net Book Cost Depreciation Value Equipment leased or held for use Theater system components $ 224,890 $ 89,218 $ 135,672 Camera equipment 5,739 3,732 2,007 230,629 92,950 137,679 Assets under construction 18,315 - 18,315 Other property, plant and equipment Land 8,203 - 8,203 Buildings 69,861 14,877 54,984 Office and production equipment 41,128 21,935 19,193 Leasehold improvements 10,067 3,026 7,041 129,259 39,838 89,421 $ 378,203 $ 132,788 $ 245,415

Other Intangible Assets

Other Intangible Assets	3 Months Ended
	Mar. 31, 2017
Other Intangible Assets [Abstract]
Other Intangible Assets	6. Other Intangible Assets As at March 31, 2017 Accumulated Net Book Cost Amortization Value Patents and trademarks $ 11,578 $ 7,216 $ 4,362 Licenses and intellectual property 21,167 6,522 14,645 Other 16,686 4,587 12,099 $ 49,431 $ 18,325 $ 31,106 As at December 31, 2016 Accumulated Net Book Cost Amortization Value Patents and trademarks $ 11,395 $ 7,046 $ 4,349 Licenses and intellectual property 22,490 7,620 14,870 Other 15,352 4,155 11,197 $ 49,237 $ 18,821 $ 30,416 Other intangible assets of $ 16.7 million are comprised mainly of the Company’s investment in an enterprise resource planning system. Fully amortized other intangible assets are still in use by the Company. During the three months ended March 31, 2017 , the Company acquired $ 1.6 million in other intangible assets. The weighted average amortization period for these additions was 10 years. During the three months ended March 31, 2017 , the Company incurred costs of $ 0.1 million, to renew or extend the term of acquired other intangible assets which were recorded in selling, general and administrative expenses ( 2016 – $0.1 million). As at March 31, 2017 , estimated amortization expense for each of the years ended December 31, are as follows: 2017 (nine months remaining) $ 2,774 2018 3,699 2019 3,699 2020 3,699 2021 3,699

Credit Facility and Playa Vista

Credit Facility and Playa Vista Loan	3 Months Ended
	Mar. 31, 2017
Credit Facility and Playa Vista Loan [Abstract]
Credit Facility and Playa Vista Construction Loan [Text Block]	7. Credit Facility and Playa Vista Loan The Company maintains a senior secured credit facility (the “Credit Facility”) with a maximum borrowing capacity of $ 200.0 million and a scheduled maturity of March 3, 2020. The Credit Facility is collateralized by a first priority security interest in substantially all of the present and future assets of the Company and the Guarantors. Certain of the Company’s subsidiaries serve as guarantors (the “Guarantors”) of the Company’s obligations under the Credit Facility. The terms of the Credit Facility are set forth in the Fourth Amended and Restated Credit Agreement (as amended, the “Credit Agreement”), dated March 3, 2015, among the Company, the Guarantors, the lenders named therein, Wells Fargo Bank, National Association (“Wells Fargo”), as agent and issuing lender (Wells Fargo, together with the lenders named therein, the “Lenders”) and Wells Fargo Securities, LLC, as Sole Lead Arranger and Sole Bookrunner and in various collateral and security documents entered into by the Company and the Guarantors. Each of the Guarantors has also entered into a guarantee in respect of the Company’s obligations under the Credit Facility. On February 22, 2016, the Company amended the terms of the Credit Agreement to increase the general restricted payment basket thereunder (which covers, among other things, the repurchase of shares) from $150.0 million to $350.0 million in the aggregate after the amendment date. The Company was in compliance with all of its requirements at March 31, 2017 . Total amounts drawn and available under the Credit Facility at March 31, 2017 were $nil and $ 200.0 million, respectively (December 31, 2016 — $nil and $ 200.0 million, respectively). As at March 31, 2017 , the Company did not have any letters of credit and advance payment guarantees outstanding (December 31, 2016 — $nil), under the Credit Facility. Playa Vista Financing IMAX PV Development Inc., a Delaware corporation (“PV Borrower”) and wholly-owned subsidiary of the Company, entered into a loan agreement with Wells Fargo. The loan (the “Playa Vista Loan”) was used to principally fund the costs of development and construction of the West Coast headquarters of the Company, located in the Playa Vista neighborhood of Los Angeles, California (the “Playa Vista Project”). In connection with the Playa Vista Project, the Playa Vista Loan was fully drawn at $30.0 million and bears interest at a variable rate per annum equal to 2.0% above the 30-day LIBOR rate. PV Borrower is required to make monthly payments of combined principal and interest over a 10-year term with a lump sum payment at the end of year 10. The Playa Vista Loan is being amortized over 15 years. The Playa Vista Loan will be fully due and payable on October 19, 2025 (the “Maturity Date”), and may be prepaid at any time without premium, but with all accrued interest and other applicable payments. The Playa Vista Loan is secured by a deed of trust from PV Borrower in favor of Wells Fargo and other documents evidencing and securing the loan (the “Loan Documents”), granting a first lien on and security interest in the Playa Vista property and the Playa Vista Project, including all improvements to be constructed thereon. The Loan Documents include absolute and unconditional payment and completion guarantees provided by the Company to Wells Fargo for the performance by PV Borrower of all the terms and provisions of the Playa Vista Loan. The Loan Documents contain affirmative, negative and financial covenants (including compliance with the financial covenants of the Company’s outstanding Credit Facility), agreements, representations, warranties, borrowing conditions, and events of default customary for development projects such as the Playa Vista Project. Bank indebtedness includes the following: March 31, December 31, 2017 2016 Playa Vista Loan $ 27,167 $ 27,667 Deferred charges on debt financing (341) (351) $ 26,826 $ 27,316 Total amounts drawn under the loan at March 31, 2017 was $ 27.2 million (December 31, 2016 — $ 27.7 million). The effective interest rate for the three months ended March 31, 2017 was 2.85 % ( 2016 — 2.43 %). In accordance with the loan agreement, the Company is obligated to make payments on the principal of the loan as follows: 2017 (nine months remaining) $ 1,500 2018 2,000 2019 2,000 2020 2,000 2021 2,000 Thereafter 17,667 $ 27,167 Wells Fargo Foreign Exchange Facility Within the Credit Facility, the Company is able to purchase foreign currency forward contracts and/or other swap arrangements. There is no settlement risk on its foreign currency forward contracts at March 31, 2017 , as the fair value exceeded the notional value of the forward contracts. As at March 31, 2017 , the Company has $ 39.8 million in notional value of such arrangements outstanding. Bank of Montreal Facility As at March 31, 2017 , the Company has available a $ 10.0 million facility (December 31, 2016 — $ 10.0 million) with the Bank of Montreal for use solely in conjunction with the issuance of performance guarantees and letters of credit fully insured by Export Development Canada (the “Bank of Montreal Facility”). The Company did not have any letters of credit and advance payment guarantees outstanding as at March 31, 2017 (December 31, 2016 — $ 0.1 million) under the Bank of Montreal Facility.

Contingencies and Guarantees

Contingencies and Guarantees	3 Months Ended
	Mar. 31, 2017
Commitments, Contingencies and Guarantees [Abstract]
Contingencies and Guarantees	8. Contingencies and Guarantees The Company is involved in lawsuits, claims, and proceedings, including those identified below, which arise in the ordinary course of business. In accordance with the Contingencies Topic of the FASB ASC, the Company will make a provision for a liability when it is both probable that a loss has been incurred and the amount of the loss can be reasonably estimated. The Company believes it has adequate provisions for any such matters. The Company reviews these provisions in conjunction with any related provisions on assets related to the claims at least quarterly and adjusts these provisions to reflect the impacts of negotiations, settlements, rulings, advice of legal counsel and other pertinent information related to the case. Should developments in any of these matters outlined below cause a change in the Company’s determination as to an unfavorable outcome and result in the need to recognize a material provision, or, should any of these matters result in a final adverse judgment or be settled for significant amounts, they could have a material adverse effect on the Company’s results of operations, cash flows, and financial position in the period or periods in which such a change in determination, settlement or judgment occurs. The Company expenses legal costs relating to its lawsuits, claims and proceedings as incurred. On May 15, 2006, the Company initiated arbitration against Three-Dimensional Media Group, Ltd. (“3DMG”) before the International Centre for Dispute Resolution in New York (the “ICDR”), alleging breaches of the license and consulting agreements between the Company and 3DMG. On June 15, 2006, 3DMG filed an answer denying any breaches and asserting counterclaims that the Company breached the parties’ license agreement. On June 21, 2007, the ICDR unanimously denied 3DMG’s Motion for Summary Judgment filed on April 11, 2007 concerning the Company’s claims and 3DMG’s counterclaims. The proceeding was suspended on May 4, 2009 due to failure of 3DMG to pay fees associated with the proceeding. The proceeding was further suspended on October 11, 2010 pending resolution of re-examination proceedings involving one of 3DMG’s patents. Following a status conference on April 27, 2016 before the ICDR, the ICDR granted 3DMG leave to amend its answer and counterclaims, and subsequently lifted the stay in this matter. In its amended counterclaims, 3DMG seeks damages for alleged unpaid royalties and other fees under the license and consulting agreements. Discovery is currently ongoing and a final hearing before the ICDR has been scheduled for the week of July 10, 2017. Given the stage of discovery, the Company is unable to determine a range of potential damages in this matter. However, the Company believes that the amount of loss, if any, suffered in connection with the amended counterclaims would not have a material impact on the financial position or results of operations of the Company, although no assurance can be given with respect to the ultimate outcome of the arbitration. In January 2004, the Company and IMAX Theatre Services Ltd., a subsidiary of the Company, commenced an arbitration seeking damages before the International Court of Arbitration of the International Chamber of Commerce (the “ICC”) with respect to the breach by Electronic Media Limited (“EML”) of its December 2000 agreement with the Company. In June 2004, the Company commenced a related arbitration before the ICC against EML’s affiliate, E-City Entertainment (I) PVT Limited (“E-City”). On March 27, 2008, the arbitration panel issued a final award in favor of the Company in the amount of $11.3 million, consisting of past and future rents owed to the Company, plus interest and costs, as well as an additional $2,512 each day in interest from October 1, 2007 until the date the award is paid. In July 2008, E-City commenced a proceeding in Mumbai, India seeking an order that the ICC award may not be recognized in India. The Company has opposed that application on a number of grounds and seeks to have the ICC award recognized in India. On June 10, 2013, the Bombay High Court ruled that it has jurisdiction over the proceeding filed by E-City. The Company appealed that ruling to the Supreme Court of India, and on March 10, 2017, the Supreme Court set aside the Bombay High Court’s judgement and dismissed E-City’s petition. On March 29, 2017, the Company filed an Execution Application in the Bombay High Court seeking to enforce the ICC award against E-City and several related parties. On June 24, 2011, the Company commenced a proceeding in the Ontario Superior Court of Justice for recognition of the ICC final award. On December 2, 2011, the Ontario Court issued an order recognizing the final award and requiring E-City to pay the Company $30,000 to cover the costs of the application. In January 2013, the Company filed an action in the New York Supreme Court seeking to collect the amount owed to the Company by certain entities and individuals affiliated with E-City. On October 16, 2015, the New York Supreme Court denied the Company’s petition, and the Company is appealing that decision. On July 29, 2014, the Company commenced a separate proceeding to have the Canadian judgment against E-City recognized in New York, and on October 2, 2015, the New York Supreme Court granted IMAX’s request, recognizing the Canadian judgment and entering it as a New York judgment. On November 26, 2014, E-City filed a motion in the Bombay High Court seeking to enjoin IMAX from continuing the New York legal proceedings. On February 2, 2015, the Bombay High Court denied E-City’s request for an injunction. On March 16, 2015, E-City filed an appeal of this Bombay High Court decision. In March 2013, IMAX (Shanghai) Multimedia Technology Co., Ltd. (“IMAX Shanghai”), the Company’s majority-owned subsidiary in China, received notice from the Shanghai office of the General Administration of Customs (“Customs Authority”) that it had been selected for a customs audit (the “Audit”). A key issue raised by the Audit is the transfer pricing policy basis for the importation of IMAX theater systems by IMAX Shanghai into the People’s Republic of China and the applicability of customs duties and taxes to the trademark and technology license fees paid by IMAX Shanghai to the Company. In December 2016, the Customs Authority conclusively determined that any trademark, technology and warranty fees paid by IMAX Shanghai on systems revenue directly related to imported theater systems should be included as part of the tax cost base of these systems and subject to applicable duties and taxes. In connection with the conclusion, for the period beginning January 1, 2012 through October 31, 2016, IMAX Shanghai recorded $2.95 million in duties and taxes on the trademark, technology and warranty fees applicable to theater systems imported during that period and settled the payment in January 2017. In the course of the Audit, the Customs Authority discovered the underpayment by IMAX Shanghai of the freight and insurance portion of the customs duties and taxes applicable to the importation of certain IMAX theater systems during the period from October 2011 through March 2013 of approximately $0.1 million. Though IMAX Shanghai’s importation agent accepted responsibility for the error giving rise to the underpayment, the matter has been transferred to the Anti-Smuggling Bureau of the Customs Authority for further review. IMAX Shanghai is unable to assess the potential impact, if any, of this outstanding matter at this time. On November 11, 2013, Giencourt Investments, S.A. (“Giencourt”) initiated arbitration before the International Centre for Dispute Resolution in Miami, Florida, based on alleged breaches by the Company of its theater agreement and related license agreement with Giencourt. Giencourt submitted its statement of claim in January 2015, the Company submitted its statement of defense and counterclaim in April 2015 and Giencourt submitted its arbitration reply paper in September 2015. An arbitration hearing for witness testimony was held during the week of December 14, 2015. At the hearing, Giencourt’s expert identified monetary damages of up to approximately $10.4 million, which Giencourt seeks to recover from the Company. The Company has asserted a counterclaim against Giencourt for breach of contract and seeks to recover lost profits in excess of $24.0 million under the agreements. In addition, on December 10, 2015, Giencourt made a motion to the panel seeking to enforce a purported settlement of the matter based on negotiations between Giencourt and the Company. The panel held a final hearing with closing arguments on October 20 and 21, 2016. On February 7, 2017, the panel issued a Partial Final Award (the “Award”), which held that the parties had reached a binding settlement, and therefore the panel did not reach the merits of the dispute. The Company strongly disputes that discussions about a potential resolution of this matter amounted to an enforceable settlement. The Company is currently reviewing the Award and assessing its response and potential next steps, including a potential challenge in Florida court on the grounds that the panel exceeded its jurisdiction. At this time, the Company is unable to determine the amounts that it may owe pursuant to the Award, or the timing of any such payments, and therefore no assurances can be given with respect to the ultimate outcome of the matter . In addition to the matters described above, the Company is currently involved in other legal proceedings or governmental inquiries which, in the opinion of the Company’s management, will not materially affect the Company’s financial position or future operating results, although no assurance can be given with respect to the ultimate outcome of any such proceedings. In the normal course of business, the Company enters into agreements that may contain features that meet the definition of a guarantee. The Guarantees Topic of the FASB ASC defines a guarantee to be a contract (including an indemnity) that contingently requires the Company to make payments (either in cash, financial instruments, other assets, shares of its stock or provision of services) to a third party based on (a) changes in an underlying interest rate, foreign exchange rate, equity or commodity instrument, index or other variable, that is related to an asset, a liability or an equity security of the counterparty, (b) failure of another party to perform under an obligating agreement or (c) failure of another third party to pay its indebtedness when due. Financial Guarantees The Company has provided no significant financial guarantees to third parties. Product Warranties The Company’s accrual for product warranties, that was recorded as part of accrued liabilities in the condensed consolidated balance sheets is less than $0.1 million at March 31, 2017 and December 31, 2016 , respectively. Director/Officer Indemnifications The Company’s General By-law contains an indemnification of its directors/officers, former directors/officers and persons who have acted at its request to be a director/officer of an entity in which the Company is a shareholder or creditor, to indemnify them, to the extent permitted by the Canada Business Corporations Act , against expenses (including legal fees), judgments, fines and any amounts actually and reasonably incurred by them in connection with any action, suit or proceeding in which the directors and/or officers are sued as a result of their service, if they acted honestly and in good faith with a view to the best interests of the Company. The nature of the indemnification prevents the Company from making a reasonable estimate of the maximum potential amount it could be required to pay to counterparties. The Company has purchased directors’ and officers’ liability insurance. No amount has been accrued in the condensed consolidated balance sheet as at March 31, 2017 and December 31, 2016 with respect to this indemnity. Other Indemnification Agreements In the normal course of the Company’s operations, the Company provides indemnifications to counterparties in transactions such as: theater system lease and sale agreements and the supervision of installation or servicing of the theater systems; film production, exhibition and distribution agreements; real property lease agreements; and employment agreements. These indemnification agreements require the Company to compensate the counterparties for costs incurred as a result of litigation claims that may be suffered by the counterparty as a consequence of the transaction or the Company’s breach or non-performance under these agreements. While the terms of these indemnification agreements vary based upon the contract, they normally extend for the life of the agreements. A small number of agreements do not provide for any limit on the maximum potential amount of indemnification; however, virtually all of the Company’s system lease and sale agreements limit such maximum potential liability to the purchase price of the system. The fact that the maximum potential amount of indemnification required by the Company is not specified in some cases prevents the Company from making a reasonable estimate of the maximum potential amount it could be required to pay to counterparties. Historically, the Company has not made any significant payments under such indemnifications and no amounts have been accrued in the condensed consolidated financial statements with respect to the contingent aspect of these indemnities.

Condensed Consolidated Statem16

Condensed Consolidated Statements of Operations Supplemental Information	3 Months Ended
	Mar. 31, 2017
Basis of Presentation and Condensed Consolidated Statements of Operations Supplemental Information [Abstract]
Condensed Consolidated Statements of Operations Supplemental Information	9. Condensed Consolidated Statements of Operations Supplemental Information Selling Expenses The Company defers direct selling costs such as sales commissions and other amounts related to its sale and sales-type lease arrangements until the related revenue is recognized. These costs and direct advertising and marketing, included in costs and expenses applicable to revenues-equipment and product sales, totaled $ 0.4 million for the three months ended March 31, 2017 ( 2016 — $ 0.7 million). Film exploitation costs, including advertising and marketing, totaled $ 2.4 million for the three months ended March 31, 2017 ( 2016 — $ 3.0 million) and are recorded in costs and expenses applicable to revenues-services as incurred. Commissions are recognized as costs and expenses applicable to revenues-rentals in the month they are earned. These costs totaled $ 0.1 million for the three months ended March 31, 2017 ( 2016 — recovery of less than $ 0.1 million). Direct advertising and marketing costs for each theater are charged to costs and expenses applicable to revenues-rentals as incurred. These costs totaled an expense of $ 0.3 million for the three months ended March 31, 2017 ( 2016 — less than $ 0.1 million). Foreign Exchange Included in selling, general and administrative expenses for the three months ended March 31, 2017 is a loss of less than $ 0.1 million ( 2016 — gain of $ 0.5 million), for net foreign exchange gains/losses related to the translation of foreign currency denominated monetary assets and liabilities. See note 15(d) for additional information. Collaborative Arrangements Joint Revenue Sharing Arrangements In a joint revenue sharing arrangement, the Company receives a portion of a theater’s box-office and concession revenues, and in some cases a small upfront or initial payment, in exchange for placing a theater system at the theater operator’s venue. Under joint revenue sharing arrangements, the customer has the ability and the right to operate the hardware components or direct others to operate them in a manner determined by the customer. The Company’s joint revenue sharing arrangements are typically non-cancellable for 10 years or longer with renewal provisions. Title to equipment under joint revenue sharing arrangements generally does not transfer to the customer. The Company’s joint revenue sharing arrangements do not contain a guarantee of residual value at the end of the term. The customer is required to pay for executory costs such as insurance and taxes and is required to pay the Company for maintenance and extended warranty throughout the term. The customer is responsible for obtaining insurance coverage for the theater systems commencing on the date specified in the arrangement’s shipping terms and ending on the date the theater systems are delivered back to the Company. The Company has signed joint revenue sharing agreements with 46 exhibitors for a total of 997 theater systems, of which 649 theaters were operating as at March 31, 2017 , the terms of which are similar in nature, rights and obligations. The accounting policy for the Company’s joint revenue sharing arrangements is disclosed in note 2(m) of the Company’s 2016 Form 10-K. Amounts attributable to transactions arising between the Company and its customers under joint revenue sharing arrangements are included in Equipment and Product Sales and Rentals revenue and for the three months ended March 31, 2017 amounted to $ 15.7 million ( 2016 — $ 23.4 million). IMAX DMR In an IMAX DMR arrangement, the Company transforms conventional motion pictures into the Company’s large screen format, allowing the release of Hollywood content to the global IMAX theater network. In a typical IMAX DMR film arrangement, the Company receives a percentage, which in recent years has averaged approximately 12.5%, of net box-office receipts, defined as gross box office receipts less applicable sales taxes, of any commercial films released in the IMAX theater network outside of Greater China from the applicable film studio for the conversion of the film to the IMAX DMR format and for access to the Company’s premium distribution platform. Within Greater China, the Company receives a lower percentage of box-office receipts for certain films. The Company does not typically hold distribution rights or the copyright to those films. For the three months ended March 31, 2017 , the majority of IMAX DMR revenue was earned from the exhibition of 18 IMAX DMR films ( 2016 – 17 ) throughout the IMAX theater network. The accounting policy for the Company’s IMAX DMR arrangements is disclosed in note 2(m) of the Company’s 2016 Form 10-K. Amounts attributable to transactions arising between the Company and its customers under IMAX DMR arrangements are included in Services revenue and for the three months ended March 31, 2017 amounted to $ 23.4 million ( 2016 — $ 29.8 million). Co-Produced Film Arrangements In certain film arrangements, the Company co-produces a film with a third party whereby the third party retains the copyright and rights to the film and the Company obtains exclusive theatrical distribution rights to the film. Under these arrangements, both parties contribute funding to the Company’s wholly-owned production company for the production of the film and for associated exploitation costs. Clauses in the film arrangements generally provide for the third party to take over the production of the film if the cost of the production exceeds its approved budget or if it appears as though the film will not be delivered on a timely basis. The accounting policies relating to co-produced film arrangements are disclosed in notes 2(a) and 2(m) of the Company’s 2016 Form 10-K. As at March 31, 2017 , the Company has one significant co-produced film arrangement which represents the VIE total assets and liabilities balance of $ 0.4 million and four other co-produced film arrangements, the terms of which are similar. For the three months ended March 31, 2017 , amounts totaling $ 0.5 million ( 2016 — $ 0.2 million) attributable to transactions between the Company and other parties involved in the production of the films have been included in cost and expenses applicable to revenues-services.

Condensed Consolidated Statem17

Condensed Consolidated Statements of Cash Flows Supplemental Information	3 Months Ended
	Mar. 31, 2017
Condensed Consolidated Statements of Cash Flows Supplemental Information [Abstract]
Condensed Consolidated Statements of Cash Flows Supplemental Information	10. Condensed Consolidated Statements of Cash Flows Supplemental Information Changes in other non-cash operating assets and liabilities are comprised of the following: Three Months Ended March 31, 2017 2016 Decrease (increase) in: Accounts receivable $ 161 $ 6,070 Financing receivables 1,763 (1,748) Inventories (3,312) (5,994) Prepaid expenses (1,421) (2,345) Commissions and other deferred selling expenses (228) 34 Insurance recoveries (96) 132 Other assets 100 (441) Increase (decrease) in: Accounts payable (6,041) (2,470) Accrued and other liabilities (18,825) (12,023) Deferred revenue 10,619 (2,998) $ (17,280) $ (21,783) Cash payments made on account of: Three Months Ended March 31, 2017 2016 Income taxes $ 7,270 $ 12,051 Interest $ 190 $ 180 Depreciation and amortization are comprised of the following: Three Months Ended March 31, 2017 2016 Film assets $ 3,805 $ 3,356 Property, plant and equipment Joint revenue sharing arrangements 4,246 3,738 Other property, plant and equipment 2,760 2,326 Other intangible assets 926 672 Other assets 220 205 Deferred financing costs 131 141 $ 12,088 $ 10,438 Write-downs, net of recoveries, are comprised of the following: Three Months Ended March 31, 2017 2016 Accounts receivable $ 185 $ 126 Inventories - 184 Film assets (1) 3,416 - Property, plant and equipment (2) 409 329 Other intangible assets - 9 $ 4,010 $ 648 __________ (1) The Company reviewed the carrying value of certain documentary film assets as a result of lower than expected revenue being generated during the period and revised expectations for future revenues based on the latest information available. An impairment of $3.4 million was recorded based on the carrying value of these documentary films as compared to the related estimated future box office and revenues that would ultimately be generated by these films. (2) The Company recognized asset impairment charges of against property, plant and equipment after an assessment of the carrying value of certain assets in light of their future expected cash flows.

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2017
Income Taxes [Abstract]
Income Taxes	11. Income Taxes Income Taxes The Company’s effective tax rate differs from the statutory tax rate and varies from year to year primarily as a result of permanent differences, investment and other tax credits, the provision for income taxes at different rates in foreign and other provincial jurisdictions, enacted statutory tax rate increases or reductions in the year, changes due to foreign exchange, changes in the Company’s valuation allowance based on the Company’s recoverability assessments of deferred tax assets, and favorable or unfavorable resolution of various tax examinations. During the quarter ended March 31, 2017 , there was no change in the Company’s estimates of the recoverability of its deferred tax assets based on an analysis of both positive and negative evidence including projected future earnings. As at March 31, 2017 , the Company had net deferred income tax assets after valuation allowance of $ 29.5 million (December 31, 2016 — $ 20.8 million), which consists of a gross deferred income tax asset of $ 29.7 million (December 31, 2016 — $ 21.0 million), against which the Company is carrying a $ 0.2 million valuation allowance (December 31, 2016 — $ 0.2 million). For the quarter ended March 31, 2017 , the Company recorded a provision for income taxes of $0.1 million. Included in the provision for income taxes was a $0.3 million recovery for windfall tax benefits, offset by a $0.6 million provision related to the portion of losses applicable to non-controlling interests in the Company’s Film Fund. The Company has elected to early adopt ASU 2016-16 related to income taxes during the quarter ended March 31, 2017. The impact from the adoption was reflected in the Company’s condensed consolidated financial statements on a modified retrospective basis resulting in an increase to Accumulated deficit of $8.3 million, a decrease to Other assets of $14.8 million, an increase to Deferred taxes of $7.9 million and an increase to Accrued and other liabilities of $1.4 million. The Company early adopted ASU 2016-09, related to stock-based compensation, in June 2016. ASU 2016-09 eliminates additional paid in capital ("APIC") pools and requires excess tax benefits and tax deficiencies to be recorded in the condensed consolidated statements of operations when the awards vest or are settled. In addition, modified retrospective adoption of ASC 2016-09 eliminates the requirement that excess tax benefits be realized before they can be recognized. The Company has recorded an adjustment of $0.9 million to Deferred income taxes related to the impact from adoption of the provisions related to forfeiture rates. See note 12 for further discussion of the impact from the adoption of ASU 2016-09. Income Tax Effect on Other Comprehensive Income The income tax expense included in the Company’s other comprehensive income are related to the following items: Three Months Ended March 31, 2017 2016 Unrealized change in cash flow hedging instruments $ (82) $ (574) Realized change in cash flow hedging instruments upon settlement (75) (332) Amortization of actuarial loss on postretirement benefit plan - (5) $ (157) $ (911)

Capital Stock

Capital Stock	3 Months Ended
	Mar. 31, 2017
Capital Stock [Abstract]
Capital Stock	12. Capital Stock Stock-Based Compensation The compensation costs recorded in the condensed consolidated statements of operations for the Company’s stock-based compensation plans were $ 5.3 million for the three months ended March 31, 2017 ( 2016 —$ 5.9 million). As at March 31, 2017 , the Company has reserved a total of 11,226,190 (December 31, 2016 — 12,012,572 ) common shares for future issuance under the Company’s Stock Option Plan (“SOP”) and the IMAX Corporation Amended and Restated Long-Term Incentive Plan (“IMAX LTIP”). Of the common shares reserved for issuance, there are options in respect of 5,268,603 common shares and restricted share units (“RSUs”) in respect of 1,275,421 common shares outstanding at March 31, 2017 . At March 31, 2017 , options in respect of 3,945,034 common shares were vested and exercisable. The Company early adopted ASU 2016-09, related to stock-based compensation, in June 2016. ASU 2016-09 eliminates the requirement to estimate and apply a forfeiture rate to reduce stock compensation expense during the vesting period and, instead, account for forfeitures as they occur. ASU 2016-09 also requires the presentation of employee taxes as a financing activity on the condensed consolidated statement of cash flows. Where applicable, comparative figures have been restated as if the adoption of ASU 2016-09 occurred on January 1, 2016. Stock Option Plan The Company recorded an expense of $ 1.3 million for the three months ended March 31, 2017 ( 2016 — $ 2.4 million) related to stock option grants issued to employees and directors in the IMAX LTIP and SOP plans. An income tax benefit is recorded in the condensed consolidated statements of operations of $ 0.4 million for the three months ended March 31, 2017 ( 2016 — $ 1.3 million), for these costs. The weighted average fair value of all stock options granted to employees and directors for the three months ended March 31, 2017 at the grant date was $ 9.08 per share ( 2016 — $ 8.55 per share). The following assumptions were used to estimate the average fair value of the stock options: Three Months Ended March 31, 2017 2016 Average risk-free interest rate 2.40% 1.72% Expected option life (in years) 4.71 - 5.83 4.79 - 4.88 Expected volatility 30% 30% Dividend yield 0% 0% Stock options to Non-Employees There were no common share options issued to non-employees during the three months ended March 31, 2017 and 2016 . As at March 31, 2017 , non-employee stock options outstanding amounted to 17,000 stock options ( 2016 — 38,750 ) with a weighted average exercise price of $ 29.64 per share ( 2016 — $ 26.79 per share ). 17,000 stock options ( 2016 — 26,325 ) were exercisable with an average weighted exercise price of $ 29.64 per share ( 2016 — $ 26.99 per share ) and the vested stock options have an aggregate intrinsic value of $ 0.1 million ( 2016 — $ 0.1 million). For the three months ended March 31, 2017 , the Company recorded an expense of less than $0.1 million ( 2016 — recovery of less than $0.1 million) to selling, general and administrative expenses related to the non-employee stock options. There were no liabilities accrued for non-employee stock options as at March 31, 2017 (December 31, 2016 — less than $0.1 million). China Long Term Incentive Plan (“China LTIP”) The China LTIP was adopted by IMAX China Holding, Inc. (“IMAX China”), a subsidiary of the Company, in October 2012. Each stock option (“China Option”), RSU or cash settled share-based payment (“CSSBP”) issued under the China LTIP represents an opportunity to participate economically in the future growth and value creation of IMAX China. In connection with the IMAX China IPO and in accordance with the China LTIP, IMAX China adopted a post-IPO share option plan and a post-IPO restricted stock unit plan. Pursuant to these plans, IMAX China issued additional China Options and China LTIP Restricted Share Units (“China RSUs”) for the three months ended March 31, 2017 . During the three months ended March 31, 2017 , the Company recorded an expense related to the China Options, China RSUs and CSSBPs of $0.2 million, $0.1 million and $0.1 million ( 2016 — $0.2 million, $nil and $0.1 million). The liability recognized with respect to the CSSBPs as at March 31, 2017 was $0.4 million (December 31, 2016 — $0.3 million). Stock Option Summary The following table summarizes certain information in respect of option activity under the SOP and IMAX LTIP for the three month periods ended March 31 : Weighted Average Exercise Number of Shares Price Per Share 2017 2016 2017 2016 Options outstanding, beginning of period 5,190,542 4,805,244 $ 28.35 $ 27.03 Granted 679,030 323,925 32.16 31.85 Exercised (584,589) (43,750) 22.38 16.91 Forfeited (16,380) (2,042) 31.69 31.85 Options outstanding, end of period 5,268,603 5,083,377 29.49 27.42 Options exercisable, end of period 3,945,034 3,507,573 28.68 26.52 No stock options were cancelled from its IMAX LTIP or SOP surrendered by Company employees during the three months ended March 31, 2017 and 2016 . As at March 31, 2017 , options that are exercisable have an intrinsic value of $ 21.3 million and a weighted average remaining contractual life of 4.6 years. The intrinsic value of options exercised in the three months ended March 31, 2017 was $ 6.0 million ( 2016 — $ 0.6 million). Restricted Share Units RSUs have been granted to employees, consultants and directors under the IMAX LTIP. Each RSU represents a contingent right to receive one common share and is the economic equivalent of one common share. The grant date fair value of each RSU is equal to the share price of the Company’s stock at the grant date. The Company recorded an expense of $ 3.4 million for the three months ended March 31, 2017 ( 2016 — $ 3.1 million), related to RSU grants issued to employees and directors in the plan. The Company did not issue any RSU grants to certain advisors and strategic partners of the Company during the three months ended March 31, 2017 and 2016 . During the three months ended March 31, 2017 , in connection with the vesting of RSUs, the Company settled 201,793 ( 2016 — 190,298 ) common shares to IMAX LTIP participants, of which 7,127 ( 2016 — 5,563 ) common shares, net of shares withheld for tax withholdings of 4,582 ( 2016 — 3,508 ) were issued from treasury and 190,084 ( 2016 — 181,227 ) common shares were settled through the open market purchases by the IMAX LTIP trustee. Total stock-based compensation expense related to non-vested RSUs not yet recognized at March 31, 2017 and the weighted average period over which the awards are expected to be recognized is $ 37.1 million and 2.6 years, respectively ( 2016 — $ 32.0 million and 2.7 years, respectively). The Company’s actual tax benefits realized for the tax deductions related to the vesting of RSUs was $ 1.9 million for the three months ended March 31, 2017 ( 2016 — $ 1.9 million). Historically, RSUs granted under the IMAX LTIP have vested between immediately and four years from the grant date. In connection with the amendment and restatement of the IMAX LTIP at the Company’s annual and special meeting of shareholders on June 6, 2016, the IMAX LTIP plan was amended to impose a minimum one-year vesting period on future RSU grants, with a carve-out for 300,000 RSUs that may vest on a shorter schedule. During 2016, 39,726 RSUs with a vesting period of less than one year were issued from the carve-out of 300,000 RSUs under the amended IMAX LTIP plan. There were no RSUs issued during the three months ended March 31, 2017 from the remaining carve-out balance of 260,274 RSUs. Vesting of the RSUs is subject to continued employment or service with the Company. The following table summarizes certain information in respect of RSU activity under the IMAX LTIP for the three months ended March 31 : Number of Awards Weighted Average Grant Date Fair Value Per Share 2017 2016 2017 2016 RSUs outstanding, beginning of period 1,124,180 973,637 $ 33.01 $ 32.27 Granted 373,540 351,584 32.45 31.85 Vested and settled (201,793) (190,298) 31.25 29.47 Forfeited (20,506) (3,092) 32.31 32.43 RSUs outstanding, end of period 1,275,421 1,131,831 33.13 32.61 Issuer Purchases of Equity Securities On June 16, 2014, the Company’s board of directors approved a new $150.0 million share repurchase program for shares of the Company’s common stock, which program was amended on April 20, 2016 to increase the aggregate purchase allowance to $200.0 million. Purchases under the program commenced during the third quarter of 2014, and the program expires on June 30, 2017. The repurchases may be made either in the open market or through private transactions, subject to market conditions, applicable legal requirements and other relevant factors. The Company has no obligation to repurchase shares and the share repurchase program may be suspended or discontinued by the Company at any time. During the three months ended March 31, 2017 , the Company did not repurchase any common shares. During the three months ended March 31, 2016 , the Company repurchased 1,446,418 common shares at an average price of $ 30.82 per share. The retired shares were purchased for $ 44.6 million. The average carrying value of the stock retired was deducted from common stock and the remaining excess over the average carrying value of stock was charged to accumulated deficit. The Company has $46.3 million available under its approved repurchase program. The total number of shares purchased during the three months ended March 31, 2017 does not include any shares purchased in the administration of employee share-based compensation plans (which amounted to 368,624 ( 2016 — 181,277) common shares, at an average price of $32.38 ( 2016 — $32.28) per share). As at March 31, 2017 , the IMAX LTIP trustee held 23,706 (December 31, 2016 — 66,093) shares purchased for $0.8 million (December 31, 2016 — $2.0 million) in the open market to be issued upon the settlement of RSUs and stock options. The shares held with the trustee are recorded at cost and are reported as a reduction against capital stock on the condensed consolidated balance sheet. Canadian Securities Law Matters The Company has received an exemption decision issued by the Ontario Securities Commission, dated April 1, 2016, for relief from the formal issuer bid requirements under Canadian securities laws. The exemption decision permits the Company to repurchase up to 10% of its outstanding common shares in any twelve-month period through the facilities of the New York Stock Exchange (“NYSE”) under repurchase programs that the Company may implement from time to time. The Canadian securities laws regulate an issuer’s ability to make repurchases of its own securities. The Company sought the exemption so that it can make repurchases under its repurchase programs in excess of the maximum allowable in reliance on the existing “other published markets” exemption from the formal issuer bid requirements available under Canadian securities laws. The “other published markets” exemption caps the Company’s ability to repurchase its securities through the facilities of the NYSE at 5% of the issuer’s outstanding securities during any 12-month period. The conditions of the exemption decision are as follows: (i) any repurchases made in reliance on the exemption decision must be permitted under, and part of repurchase programs established and conducted in accordance with, U.S. securities laws and NYSE rules, (ii) the aggregate number of common shares acquired in reliance on the exemption decision by the Company and any person or company acting jointly or in concert with the Company within any 12 months does not exceed 10% of the outstanding common shares at the beginning of the 12-month period, (iii) the common shares are not listed and posted for trading on an exchange in Canada, (iv) the exemption decision applies only to the acquisition of common shares by the Company within 36 months of the date of the decision, and (v) prior to purchasing common shares in reliance on the exemption decision, the Company discloses the terms of the exemption decision and the conditions applicable thereto in a press release that is issued on SEDAR and includes such language as part of the news release required to be issued in accordance with the “other published markets exemption” in respect of any repurchase program that may be implemented by the Company. Net Income Per Share Reconciliations of the numerator and denominator of the basic and diluted per-share computations are comprised of the following: Three Months Ended March 31, 2017 2016 Net income applicable to common shareholders $ 75 $ 11,302 Weighted average number of common shares (000's): Issued and outstanding, beginning of period 66,160 69,673 Weighted average number of shares issued (repurchased) during the period 203 (294) Weighted average number of shares used in computing basic income per share 66,363 69,379 Assumed exercise of stock options and RSUs, net of shares assumed repurchased 817 741 Weighted average number of shares used in computing diluted income per share 67,180 70,120 The calculation of diluted earnings per share excludes 1,785,013 shares that are issuable upon the vesting of 171,673 RSUs and the exercise of 1,613,340 stock options for the three months ended March 31, 2017 , as the impact would be antidilutive. The calculation of diluted earnings per share excludes 3,245,033 shares that are issuable upon the vesting of 615,028 RSUs and the exercise of 2,630,005 stock options for the three months ended March 31, 2016 , as the impact would be antidilutive. As part of the adoption of ASU 2016-09, the excess tax benefit is no longer included in the calculation of diluted shares under the treasury stock method. Shareholder’s Equity Attributable to Common Shareholders The following summarizes the movement of Shareholders’ Equity attributable to common shareholders for the three months ended March 31, 2017 : Balance as at December 31, 2016 $ 562,012 Net income attributable to common shareholders 75 Retrospective adjustment related to intra-entity transfers (notes 2 and 11) (8,314) Adjustments to capital stock: Cash received from the issuance of common shares 13,082 Issuance of common shares for vested RSUs 273 Fair value of stock options exercised at the grant date 3,270 Share held in treasury 1,160 Adjustments to other equity: Employee stock options granted 1,596 Non-employee stock options granted and vested 17 Fair value of stock options exercised at the grant date (3,270) RSUs granted 3,554 RSUs vested (6,506) Stock exercised from treasury shares (7,025) Adjustments to accumulated other comprehensive loss: Unrealized net gain from cash flow hedging instruments 313 Realization of cash flow hedging net loss upon settlement 285 Foreign currency translation adjustments 312 Tax effect of movement in other comprehensive income (157) Balance as at March 31, 2017 $ 560,677

Segmented Information

Segmented Information	3 Months Ended
	Mar. 31, 2017
Segmented Information [Abstract]
Segmented Information	13. Segmented Information Management, including the Company’s Chief Executive Officer (“CEO”) who is the Company’s Chief Operating Decision Maker (as defined in the Segment Reporting Topic of the FASB ASC), assesses segment performance based on segment revenues, gross margins and film performance. Selling, general and administrative expenses, research and development costs, amortization of intangibles, receivables provisions (recoveries), write-downs net of recoveries, interest income, interest expense and tax (provision) recovery are not allocated to the segments. In the first quarter of 2017, modifications have been made to the CEO’s reporting package to move away from the Company’s historical two primary groups – IMAX Theater Systems and Film – and align with the way in which the CODM manages the business. The new structure is expected to assist users of the financial statements with an enhanced understanding of how management views the business, and the drivers behind the Company’s performance. C ertain of the prior period’s figures have been reclassified to conform to the current period’s presentation. The Company has identified new business as an additional reportable segment in the first quarter of 2017. The Company now has the following eight reportable segments: IMAX systems; IMAX DMR; joint revenue sharing arrangements; theater system maintenance; film distribution; film post-production; new business; and other. The Company’s reportable segments are now under four primary groups identified by nature of product sold or service provided: (1) Network Business, representing variable revenue generated by box-office results and which includes the reportable segment of IMAX DMR and contingent rent from the joint revenue sharing arrangements and IMAX systems segments; (2) Theater Business, representing revenue generated by the sale and installation of theater systems and maintenance services, primarily related to the IMAX Systems and Theater System Maintenance reportable segments, and also includes fixed hybrid revenues and upfront installation costs from the joint revenue sharing arrangements segment and after-market sales of projection system parts and 3D glasses from the other segment; (3) New Business, which includes content licensing and distribution fees associated with the Company’s original content investments, virtual reality initiatives, IMAX Home Entertainment, and other business initiatives that are in the development and/or start-up phase, and (4) Other; which includes the film post-production and distribution segments and certain IMAX theaters that the Company owns and operates, camera rentals and other miscellaneous items from the other segment. The Company is presenting information at a disaggregated level to provide more relevant information to readers, as permitted by the standard. The accounting policies of the segments are the same as those described in note 2 to the audited consolidated financial statements included in the Company’s 2016 Form 10-K. In addition, refer to Item 2 of the Company’s Form 10-Q for additional information regarding the four primary groups mentioned above. Transactions between the IMAX DMR segment and the film post-production segment are valued at exchange value. Inter-segment profits are eliminated upon consolidation, as well as for the disclosures below. Three Months Ended March 31, 2017 2016 Revenue (1) Network business IMAX DMR $ 23,408 $ 29,805 Joint revenue sharing arrangements – contingent rent 15,233 21,315 IMAX systems – contingent rent 688 1,187 39,329 52,307 Theater business IMAX systems 9,527 20,674 Joint revenue sharing arrangements – fixed fees 470 2,070 Theater system maintenance 11,045 9,826 Other theater 2,165 2,487 23,207 35,057 New business 1,280 - Other Film post-production 3,072 2,407 Film distribution 512 363 Other 1,257 1,994 4,841 4,764 Total $ 68,657 $ 92,128 Gross Margin Network business IMAX DMR (2) $ 17,467 $ 22,823 Joint revenue sharing arrangements – contingent rent (2) 10,250 17,487 IMAX systems – contingent rent 688 1,187 28,405 41,497 Theater business IMAX systems (2) 5,741 6,648 Joint revenue sharing arrangements – fixed fees (2) 88 504 Theater system maintenance 4,249 3,439 Other theater 430 (32) 10,508 10,559 New business (337) (225) Other Film post-production 1,101 1,249 Film distribution (2) (3,764) (679) Other (142) (225) (2,805) 345 Total $ 35,771 $ 52,176 ___________ (1) The Company’s largest customer represented 17.2 % of total revenues for the three months ended March 31, 2017 ( 2016 — 16.0 %). (2) IMAX DMR segment margins include marketing costs of $ 2.6 million for the three months ended March 31, 2017 ( 2016 — $ 2.3 million). Joint revenue sharing arrangements segment margins include advertising, marketing and commission costs of $ 0.4 million for the three months ended March 31, 2017 ( 2016 — $ 0.1 million). IMAX systems segment margins include marketing and commission costs of $ 0.4 million for the three months ended March 31, 2017 ( 2016 — $ 0.5 million). Film distribution segment margins include a marketing recovery of $ 0.2 million for the three months ended March 31, 2017 ( 2016 — expense of $ 0.7 million). Geographic Information Revenue by geographic area is based on the location of the customer. Revenue related to IMAX DMR is presented based upon the geographic location of the theaters that exhibit the re-mastered films. IMAX DMR revenue is generated through contractual relationships with studios and other third parties and these may not be in the same geographical location as the theater. Three Months Ended March 31, 2017 2016 Revenue United States $ 25,198 $ 35,544 Canada 3,282 7,077 Greater China 18,590 24,939 Asia (excluding Greater China) 8,429 5,559 Western Europe 5,813 11,486 Russia & the CIS 3,183 1,692 Latin America 1,654 3,527 Rest of the World 2,508 2,304 Total $ 68,657 $ 92,128 No single country in the Rest of the World, Western Europe, Latin America and Asia (excluding Greater China) classifications comprises more than 10% of the total revenue.

Employees Pension and Postretir

Employees Pension and Postretirement Benefits	3 Months Ended
	Mar. 31, 2017
Employees Pension and Postretirement Benefits [Abstract]
Employees Pension and Postretirement Benefits	14. Employee's Pension and Postretirement Benefits Defined Benefit Plan The Company has an unfunded U.S. defined benefit pension plan (the “SERP”) covering Richard L. Gelfond, CEO of the Company. The following table provides disclosure of the pension obligation for the SERP: March 31, December 31, 2017 2016 Projected benefit obligation: Obligation, beginning of period $ 19,580 $ 19,478 Interest cost 107 261 Actuarial gain - (159) Obligation, end of period and unfunded status $ 19,687 $ 19,580 The following table provides disclosure of pension expense for the SERP: Three Months Ended March 31, 2017 2016 Interest cost $ 107 $ 65 Pension expense $ 107 $ 65 No contributions are expected to be made for the SERP during the remainder of 2017 . The Company expects interest costs of $ 0.3 million to be recognized as a component of net periodic benefit cost during the remainder of 2017 . The accumulated benefit obligation for the SERP was $ 19.7 million at March 31, 2017 (December 31, 2016 — $ 19.6 million). The following benefit payments are expected to be made as per the current SERP assumptions and the terms of the SERP in each of the next 5 years, and in the aggregate: 2017 (nine months remaining) $ - 2018 - 2019 - 2020 21,115 2021 - Thereafter - $ 21,115 The SERP assumptions are that Mr. Gelfond will receive a lump sum payment six months after retirement at the end of the current term of his employment agreement (December 31, 2019), although Mr. Gelfond has not informed the Company that he intends to retire at that time. Defined Contribution Pension Plan The Company also maintains defined contribution plans for its employees, including its executive officers. The Company makes contributions to these plans on behalf of employees in an amount up to 5% of their base salary subject to certain prescribed maximums. During the three months ended March 31, 2017 , the Company contributed and expensed an aggregate of $ 0.3 million ( 2016 — $ 0.4 million ) to its Canadian defined contribution plan and an aggregate of $ 0.2 million ( 2016 — $ 0.2 million ) to its defined contribution employee plan under Section 401(k) of the U.S. Internal Revenue Code. In September 2016, the Company entered into a new employment agreement with Greg Foster, CEO of IMAX Entertainment and Senior Executive Vice President of the Company, which provides for an employment term from July 2, 2016 through July 2, 2019. Under the agreement, the Company agreed to create a deferred compensation plan (the “Retirement Plan”) covering Mr. Foster, and to make a total contribution of $3.2 million over the three-year employment term. The Retirement Plan is subject to a vesting schedule based on continued employment with the Company, such that 25% will vest July 2019; 50% will vest July 2022; 75% will vest July 2025; and Mr. Foster will be 100% vested in July 2027. As at March 31, 2017, the Company had an unfunded benefit obligation recorded of $0.8 million (December 31, 2016 — $0.5 million). The Company has expensed $0.3 million for the three months ended March 31, 2017 ( 2016 — $nil). Postretirement Benefits - Executives The Company has an unfunded postretirement plan for Mr. Gelfond and Bradley J. Wechsler, Chairman of the Company’s Board of Directors. The plan provides that the Company will maintain health benefits for Messrs. Gelfond and Wechsler until they become eligible for Medicare and, thereafter, the Company will provide Medicare supplement coverage as selected by Messrs. Gelfond and Wechsler. The postretirement benefits obligation as at March 31, 2017 is $ 0.7 million (December 31, 2016 — $ 0.6 million). The Company has expensed less than $ 0.1 million for the three months ended March 31, 2017 ( 2016 — less than $0.1 million). The following benefit payments are expected to be made as per the current plan assumptions in each of the next 5 years: 2017 (nine months remaining) $ 21 2018 24 2019 26 2020 33 2021 36 Thereafter 514 Total $ 654 Postretirement Benefits – Canadian Employees The Company has an unfunded postretirement plan for its Canadian employees upon meeting specific eligibility requirements. The Company will provide eligible participants, upon retirement, with health and welfare benefits. The postretirement benefits obligation as at March 31, 2017 is $ 1.8 million (December 31, 2016 — $ 1.7 million). The Company has expensed less than $ 0.1 million for the three months ended March 31, 2017 ( 2016 — less than $ 0.1 million). The following benefit payments are expected to be made as per the current plan assumptions in each of the next 5 years: 2017 (nine months remaining) $ 92 2018 99 2019 105 2020 108 2021 110 Thereafter 1,244 Total $ 1,758

Financial Instruments

Financial Instruments	3 Months Ended
	Mar. 31, 2017
Financial Instruments [Abstract]
Financial Instruments	15. Financial Instruments Financial Instruments The Company maintains cash with various major financial institutions. The Company’s cash is invested with highly rated financial institutions. The Company’s accounts receivables and financing receivables are subject to credit risk. The Company’s accounts receivable and financing receivables are concentrated with the theater exhibition industry and film entertainment industry. To minimize the Company’s credit risk, the Company retains title to underlying theater systems leased, performs initial and ongoing credit evaluations of its customers and makes ongoing provisions for its estimate of potentially uncollectible amounts. The Company believes it has adequately provided for related exposures surrounding receivables and contractual commitments. Fair Value Measurements The carrying values of the Company’s cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities due within one year approximate fair values due to the short-term maturity of these instruments. The Company’s other financial instruments are comprised of the following: As at March 31, 2017 As at December 31, 2016 Carrying Estimated Carrying Estimated Amount Fair Value Amount Fair Value Cash and cash equivalents $ 190,481 $ 190,481 $ 204,759 $ 204,759 Net financed sales receivable $ 112,682 $ 113,792 $ 114,041 $ 115,014 Net investment in sales-type leases $ 7,808 $ 8,163 $ 8,084 $ 8,372 Convertible loan receivable $ 1,000 $ 1,000 $ 1,000 $ 1,000 Available-for-sale investment $ 1,000 $ 1,010 $ 1,000 $ 1,007 Foreign exchange contracts — designated forwards $ 302 $ 302 $ (296) $ (296) Borrowings under the Playa Vista Loan $ (27,167) $ (27,167) $ (27,667) $ (27,667) Cash and cash equivalents are comprised of cash and interest-bearing investments with original maturity dates of 90 days or less. Cash and cash equivalents are recorded at cost, which approximates fair value (Level 1 input in accordance with the Fair Value Measurements Topic of the FASB ASC hierarchy) as at March 31, 2017 and December 31, 2016 , respectively. The estimated fair values of the net financed sales receivable and net investment in sales-type leases are estimated based on discounting future cash flows at currently available interest rates with comparable terms (Level 2 input in accordance with the Fair Value Measurements Topic of the FASB ASC hierarchy) as at March 31, 2017 and December 31, 2016 , respectively. The estimated fair value of the Company’s convertible loan receivable is based on discounting future cash flows at currently available interest rates with comparable terms (Level 2 input in accordance with the Fair Value Measurements Topic of the FASB ASC hierarchy) as at March 31, 2017 and December 31, 2016 , respectively. The fair value of the Company’s available-for-sale investment is determined using quoted prices in active markets (Level 2 input in accordance with the Fair Value Measurements Topic of the FASB ASC hierarchy) as at March 31, 2017 and December 31, 2016 , respectively. The fair value of foreign currency derivatives is determined using quoted prices in active markets (Level 2 input in accordance with the Fair Value Measurements Topic of the FASB ASC hierarchy) as at March 31, 2017 and December 31, 2016 , respectively. These identical instruments are traded on a closed exchange. The carrying value of borrowings under the Playa Vista Loan approximates fair value as the interest rates offered under the Playa Vista Loan are close to March 31, 2017 market rates for the Company for debt of the same remaining maturities (Level 2 input in accordance with the Fair Value Measurements Topic of the FASB ASC hierarchy) as at March 31, 2017 . There were no significant transfers between Level 1 and Level 2 during the three months ended March 31, 2017 or 2016 . When a determination is made to classify an asset or liability within Level 3, the determination is based upon the significance of the unobservable inputs to the overall fair value measurement. There were no transfers in or out of the Company’s level 3 assets during the three months ended March 31, 2017 . Financing Receivables The Company’s net investment in leases and its net financed sale receivables are subject to the disclosure requirements of ASC 310 “Receivables”. Due to differing risk profiles of its net investment in leases and its net financed sales receivables, the Company views its net investment in leases and its net financed sale receivables as separate classes of financing receivables. The Company does not aggregate financing receivables to assess impairment. The Company monitors the credit quality of each customer on a frequent basis through collections and aging analyses. The Company also holds meetings monthly in order to identify credit concerns and whether a change in credit quality classification is required for the customer. A customer may improve in their credit quality classification once a substantial payment is made on overdue balances or the customer has agreed to a payment plan with the Company and payments have commenced in accordance to the payment plan. The change in credit quality indicator is dependent upon management approval. The Company classifies its customers into four categories to indicate the credit quality worthiness of its financing receivables for internal purposes only: Good standing — Theater continues to be in good standing with the Company as the client’s payments and reporting are up-to-date. Credit Watch — Theater operator has begun to demonstrate a delay in payments, and has been placed on the Company's credit watch list for continued monitoring, but active communication continues with the Company. Depending on the size of outstanding balance, length of time in arrears and other factors, transactions may need to be approved by management. These financing receivables are considered to be in better condition than those receivables related to theaters in the "Pre-approved transactions" category, but not in as good of condition as those receivables in "Good standing." Pre-approved transactions only — Theater operator is demonstrating a delay in payments with little or no communication with the Company. All service or shipments to the theater must be reviewed and approved by management. These financing receivables are considered to be in better condition than those receivables related to theaters in the "All transactions suspended" category, but not in as good of condition as those receivables in "Credit Watch." Depending on the individual facts and circumstances of each customer, finance income recognition may be suspended if management believes the receivable to be impaired. All transactions suspended — Theater is severely delinquent, non-responsive or not negotiating in good faith with the Company. Once a theater is classified as “All transactions suspended” the theater is placed on nonaccrual status and all revenue recognitions related to the theater are stopped. The following table discloses the recorded investment in financing receivables by credit quality indicator: As at March 31, 2017 As at December 31, 2016 Minimum Financed Minimum Financed Lease Sales Lease Sales Payments Receivables Total Payments Receivables Total In good standing $ 7,465 $ 110,249 $ 117,714 $ 7,741 $ 111,568 $ 119,309 Credit Watch - 1,683 1,683 - 1,514 1,514 Pre-approved transactions - 633 633 - 842 842 Transactions suspended 1,015 611 1,626 1,015 611 1,626 $ 8,480 $ 113,176 $ 121,656 $ 8,756 $ 114,535 $ 123,291 While recognition of finance income is suspended, payments received by a customer are applied against the outstanding balance owed. If payments are sufficient to cover any unreserved receivables, a recovery of provision taken on the billed amount, if applicable, is recorded to the extent of the residual cash received. Once the collectibility issues are resolved and the customer has returned to being in good standing, the Company will resume recognition of finance income. The Company’s investment in financing receivables on nonaccrual status is as follows: As at March 31, 2017 As at December 31, 2016 Recorded Related Recorded Related Investment Allowance Investment Allowance Net investment in leases $ 1,015 $ (672) $ 1,015 $ (672) Net financed sales receivables 611 (494) 611 (494) Total $ 1,626 $ (1,166) $ 1,626 $ (1,166) The Company considers financing receivables with aging between 60-89 days as indications of theaters with potential collection concerns. The Company will begin to focus its review on these financing receivables and increase its discussions internally and with the theater regarding payment status. Once a theater’s aging exceeds 90 days, the Company’s policy is to review and assess collectibility on the theater’s past due accounts. Over 90 days past due is used by the Company as an indicator of potential impairment as invoices up to 90 days outstanding could be considered reasonable due to the time required for dispute resolution or for the provision of further information or supporting documentation to the customer. The Company’s aged financing receivables are as follows: As at March 31, 2017 Related Recorded Accrued Billed Unbilled Total Investment and 30-89 Financing Recorded Recorded Related Net of Current Days 90+ Days Receivables Investment Investment Allowances Allowances Net investment in leases $ 41 $ 94 $ 763 $ 898 $ 7,582 $ 8,480 $ (672) $ 7,808 Net financed sales receivables 1,884 2,379 2,879 7,142 106,035 113,176 (494) 112,682 Total $ 1,925 $ 2,473 $ 3,642 $ 8,040 $ 113,617 $ 121,656 $ (1,166) $ 120,490 As at December 31, 2016 Related Recorded Accrued Billed Unbilled Total Investment and 30-89 Financing Recorded Recorded Related Net of Current Days 90+ Days Receivables Investment Investment Allowances Allowances Net investment in leases $ 28 $ 159 $ 781 $ 968 $ 7,788 $ 8,756 $ (672) $ 8,084 Net financed sales receivables 2,393 1,724 2,368 6,485 108,050 114,535 (494) 114,041 Total $ 2,421 $ 1,883 $ 3,149 $ 7,453 $ 115,838 $ 123,291 $ (1,166) $ 122,125 The Company’s recorded investment in past due financing receivables for which the Company continues to accrue finance income is as follows: As at March 31, 2017 Related Recorded Accrued Billed Unbilled Investment and Financing Recorded Related Past Due Current 30-89 Days 90+ Days Receivables Investment Allowance and Accruing Net investment in leases $ 38 $ 61 $ 293 $ 392 $ 2,237 $ - $ 2,629 Net financed sales receivables 146 968 2,280 3,394 25,876 - 29,270 Total $ 184 $ 1,029 $ 2,573 $ 3,786 $ 28,113 $ - $ 31,899 As at December 31, 2016 Related Recorded Accrued Billed Unbilled Investment and Financing Recorded Related Past Due Current 30-89 Days 90+ Days Receivables Investment Allowance and Accruing Net investment in leases $ - $ 54 $ 244 $ 298 $ 1,646 $ - $ 1,944 Net financed sales receivables 284 634 1,854 2,772 20,147 - 22,919 Total $ 284 $ 688 $ 2,098 $ 3,070 $ 21,793 $ - $ 24,863 The Company considers financing receivables to be impaired when it believes it to be probable that it will not recover the full amount of principal or interest owing under the arrangement. The Company uses its knowledge of the industry and economic trends, as well as its prior experiences to determine the amount recoverable for impaired financing receivables. The following table discloses information regarding the Company’s impaired financing receivables: For the Three Months Ended March 31, 2017 Average Interest Recorded Unpaid Related Recorded Income Investment Principal Allowance Investment Recognized Recorded investment for which there is a related allowance: Net financed sales receivables $ 525 $ 75 $ (494) $ 525 $ - Recorded investment for which there is no related allowance: Net financed sales receivables - - - - - Total recorded investment in impaired loans: Net financed sales receivables $ 525 $ 75 $ (494) $ 525 $ - For the Three Months Ended March 31, 2016 Average Interest Recorded Unpaid Related Recorded Income Investment Principal Allowance Investment Recognized Recorded investment for which there is a related allowance: Net financed sales receivables $ 748 $ 414 $ (643) $ 748 $ - Recorded investment for which there is no related allowance: Net financed sales receivables - - - - - Total recorded investment in impaired loans: Net financed sales receivables $ 748 $ 414 $ (643) $ 748 $ - The Company’s activity in the allowance for credit losses for the period and the Company’s recorded investment in financing receivables are as follows: Three Months Ended March 31, 2017 Three Months Ended March 31, 2016 Net Investment Net Financed Net Investment Net Financed in Leases Sales Receivables in Leases Sales Receivables Allowance for credit losses: Beginning balance $ 672 $ 494 $ 672 $ 568 Charge-offs - - - - Recoveries - - - - Provision - - - 75 Ending balance $ 672 $ 494 $ 672 $ 643 Ending balance: individually evaluated for impairment $ 672 $ 494 $ 672 $ 643 Financing receivables: Ending balance: individually evaluated for impairment $ 8,480 $ 113,176 $ 10,577 $ 110,387 Foreign Exchange Risk Management The Company is exposed to market risk from changes in foreign currency rates. A majority portion of the Company’s revenues is denominated in U.S. dollars while a substantial portion of its costs and expenses is denominated in Canadian dollars. A portion of the net U.S. dollar cash flows of the Company is periodically converted to Canadian dollars to fund Canadian dollar expenses through the spot market. In China and Japan the Company has ongoing operating expenses related to its operations in Chinese Renminbi and Japanese yen, respectively. Net cash flows are converted to and from U.S. dollars through the spot market. The Company also has cash receipts under leases denominated in Chinese Renminbi, Japanese yen, Canadian dollars and Euros which are converted to U.S. dollars through the spot market. In addition, because IMAX films generate box-office in 75 different countries, unfavourable exchange rates between applicable local currencies, and the U.S. dollar affect the Company’s reported gross box-office and revenues, further impacting the Company’s results of operations. The Company’s policy is to not use any financial instruments for trading or other speculative purposes. The Company entered into a series of foreign currency forward contracts to manage the Company’s risks associated with the volatility of foreign currencies. Certain of these foreign currency forward contracts met the criteria required for hedge accounting under the Derivatives and Hedging Topic of the FASB ASC at inception, and continue to meet hedge effectiveness tests at March 31, 2017 (the “Foreign Currency Hedges”), with settlement dates throughout 2017 and 2018 . Foreign currency derivatives are recognized and measured in the balance sheet at fair value. Changes in the fair value (gains or losses) are recognized in the condensed consolidated statements of operations except for derivatives designated and qualifying as foreign currency cash flow hedging instruments. For foreign currency cash flow hedging instruments, the effective portion of the gain or loss in a hedge of a forecasted transaction is reported in other comprehensive income and reclassified to the condensed consolidated statements of operations when the forecasted transaction occurs. Any ineffective portion is recognized immediately in the condensed consolidated statements of operations. The Company currently does not hold any derivatives which are not designated as hedging instruments . The following tabular disclosures reflect the impact that derivative instruments and hedging activities have on the Company’s condensed consolidated financial statements: Notional value of foreign exchange contracts: March 31, December 31, 2017 2016 Derivatives designated as hedging instruments: Foreign exchange contracts — Forwards $ 39,802 $ 37,825 Fair value of derivatives in foreign exchange contracts: March 31, December 31, Balance Sheet Location 2017 2016 Derivatives designated as hedging instruments: Foreign exchange contracts — Forwards Other assets $ 604 $ 480 Accrued and other liabilities (302) (776) $ 302 $ (296) Derivatives in Foreign Currency Hedging relationships for the three months ended March 31: Three Months Ended March 31, 2017 2016 Foreign exchange contracts — Forwards Derivative Gain Recognized in OCI (Effective Portion) $ 313 $ 2,207 Location of Derivative Loss Reclassified from AOCI Three Months Ended March 31, into Income (Effective Portion) 2017 2016 Foreign exchange contracts — Forwards Selling, general and administrative expenses $ (285) $ (1,277) Three Months Ended March 31, 2017 2016 Foreign exchange contracts - Forwards Derivative Loss Recognized In and Out of OCI (Effective Portion) $ (47) $ - The Company's estimated net amount of the existing gains as at March 31, 2017 is $ 0.4 million, which is expected to be reclassified to earnings within the next twelve months Investments in New Business Ventures The Company accounts for investments in new business ventures using the guidance of the FASB ASC 323 or FASB ASC 320, as appropriate. As at March 31, 2017 , the equity method of accounting is being utilized for an investment with a carrying value of $nil (December 31, 2016 — $nil). The Company’s accumulated losses in excess of its equity investment were $ 0.7 million as at March 31, 2017 , and are classified in Accrued and other liabilities. For the three months ended March 31, 2017 , gross revenues, cost of revenue and net loss for the Company’s investments were $ 0.2 million, $ 0.9 million and $ 0.7 million, respectively ( 2016 — $ 0.4 million , $ 2.2 million and $ 1.8 million, respectively). The Company has determined it is not the primary beneficiary of this VIE, and therefore this entity has not been consolidated. In 2016, the Company issued a convertible loan of $1.0 million to this entity with a term of 3 years with an annual effective interest rate of 5.0%. The instrument is classified as an available-for-sale investment due to certain features that allow for conversion to common stock in the entity in the event of certain triggers occurring. In addition, the Company has an investment in preferred stock of another business venture of $ 1.5 million which meet the criteria for classification as a debt security under the FASB ASC 320 and is recorded at a fair value of $ nil at March 31, 2017 (December 31, 2016 — $ nil ). This investment was classified as an available-for-sale investment. Furthermore, the Company has an investment of $ 1.0 million (December 31, 2016 — $ 1.0 million) in the shares of an exchange traded fund. This investment is also classified as an available-for-sale investment. As at March 31, 2017 , the Company held investments with a total value of $ 3.5 million in the preferred shares of enterprises which meet the criteria for classification as an equity security under FASB ASC 325, carried at historical cost, net of impairment charges. The carrying value of these equity security investments was $ 1.0 million at March 31, 2017 (December 31, 2016 — $nil). The total carrying value of investments in new business ventures at March 31, 2017 is $ 3.0 million (December 31, 2016 — $ 2.0 million) and is recorded in Other assets.

Non-Controlling Interests

Non-Controlling Interests	3 Months Ended
	Mar. 31, 2017
Temporary Equity Disclosure [Abstract]
Non-Controlling Interests [Text Block]	16. Non-Controlling Interests IMAX China Non-Controlling Interest On April 8, 2014, the Company announced sale and issuance of 20% of the shares of IMAX China to entities owned and controlled by CMC Capital Partners (“CMC”), an investment fund that is focused on media and entertainment, and FountainVest Partners (“FountainVest”), a China-focused private equity firm. The sale price for the interest was $80.0 million, and was paid by the investors in two equal installments on April 8, 2014 and February 10, 2015. On October 8, 2015, IMAX China completed the IMAX China IPO. Following the IMAX China IPO, the Company continues to indirectly own approximately 68.2% of IMAX China, which remains a consolidated subsidiary of the Company. On October 15, 2015, in satisfaction of its obligations under the shareholders’ agreement, IMAX China paid a dividend of $9.5 million to the non-controlling interest shareholders. The following summarizes the movement of the non-controlling interest in shareholders’ equity, in the Company’s subsidiary for the three months ended March 31, 2017 : Balance as at December 31, 2016 $ 59,562 Net income 1,463 Other comprehensive loss 146 Balance as at March 31, 2017 $ 61,171 Other Non-Controlling Interest In 2014, the Company announced the creation of the Film Fund to co-finance a portfolio of 10 original large-format films. The Film Fund, which is intended to be capitalized with up to $ 50.0 million, will finance an ongoing supply of original films that the Company believes will be more exciting and compelling than traditional documentaries. The initial investment in the Film Fund was committed to by a third party in the amount of $ 25.0 million, with the possibility of contributing additional funds. The Company agreed to contribute $ 9.0 million to the Film Fund over five years starting in 2014 and sees the Film Fund as a self-perpetuating vehicle designed to generate a continuous, steady flow of high-quality documentary content. As at March 31, 2017, the Film Fund invested $13.4 million toward the development of original films. The related production, financing and distribution agreement includes put and call rights relating to change of control of the rights, title and interest in the co-financed pictures. The following summarizes the movement of the non-controlling interest in temporary equity, in the Company’s subsidiary for the three months ended March 31, 2017 : Balance as at December 31, 2016 $ 4,980 Net loss (2,425) Balance as at March 31, 2017 $ 2,555

Basis of Presentation (Policies

Basis of Presentation (Policies)	3 Months Ended
	Mar. 31, 2017
Basis of Presentation and Condensed Consolidated Statements of Operations Supplemental Information [Abstract]
Basis of Accounting	All intercompany accounts and transactions, including all unrealized intercompany profits on transactions with equity-accounted investees, have been eliminated. The year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. These interim financial statements should be read in conjunction with the consolidated financial statements included in the Company’s 2016 Annual Report on Form 10-K for the year ended December 31, 2016 (“the 2016 Form 10-K”) which should be consulted for a summary of the significant accounting policies utilized by the Company. These interim financial statements are prepared following accounting policies consistent with the Company’s financial statements for the year ended December 31, 2016 , except as noted below. Certain prior period information has been revised to reflect the current period information.
Variable interest entities	The condensed consolidated financial statements include the accounts of the Company together with its consolidated subsidiaries, except for subsidiaries which the Company has identified as variable interest entities (“VIEs”) where the Company is not the primary beneficiary. The nature of the Company’s business is such that the results of operations for the interim periods presented are not necessarily indicative of results to be expected for the fiscal year. In the opinion of management, the information contained herein reflects all normal and recurring adjustments necessary to make the results of operations for the interim periods a fair statement of such operations. The Company has evaluated its various variable interests to determine whether they are VIEs as required by the Consolidation Topic of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC” or “Codification”). The Company has nine film production companies that are VIEs. For four of the Company’s film production companies, the Company has determined that it is the primary beneficiary of these entities as the Company has the power to direct the activities of the respective VIE that most significantly impact the respective VIE’s economic performance and has the obligation to absorb losses of the VIE that could potentially be significant to the respective VIE or the right to receive benefits from the respective VIE that could potentially be significant to the respective VIE. These consolidated production companies have total assets of $ 5.8 million (December 31, 2016 — $ 10.3 million) and total liabilities of $ 6.5 million as at March 31, 2017 (December 31, 2016 — $ 6.4 million). The majority of these consolidated assets are held by the IMAX Original Film Fund (the “Film Fund”) as described in note 16(b). For the other five film production companies which are VIEs, the Company did not consolidate these film entities since it does not have the power to direct activities and does not absorb the majority of the expected losses or expected residual returns. The Company equity accounts for these entities. As at March 31, 2017 , these five VIEs have total assets of $ 0.4 million (December 31, 2016 — $ 0.4 million) and total liabilities of $ 0.4 million (December 31, 2016 — $ 0.4 million). Earnings of the investees included in the Company’s condensed consolidated statements of operations amounted to $nil for the three months ended March 31, 2017 ( 2016 — $nil). The carrying value of these investments in VIEs that are not consolidated is $nil at March 31, 2017 (December 31, 2016 — $nil). A loss in value of an investment other than a temporary decline is recognized as a charge to the condensed consolidated statements of operations. The Company’s exposure, which is determined based on the level of funding contributed by the Company and the development stage of the respective film, is $nil at March 31, 2017 (December 31, 2016 — $nil).
Equity and Cost Method Investments Policy	The Company accounts for investments in new business ventures using the guidance of the FASB ASC 323 “Investments – Equity Method and Joint Ventures” (“ASC 323”) or ASC 320 “Investments in Debt and Equity Securities” (“ASC 320”), as appropriate.
New Accounting Pronouncements Adopted	In July 2015, the FASB issued ASU No. 2015-11, “Inventory (Topic 330): Simplifying the Measurement of Inventory” (“ASU 2015-11”). The purpose of the amendment is to more closely align the measurement of inventory in U.S. GAAP with the measurement of inventory in International Financial Reporting Standards. Under the ASU inventory is measured at the lower of cost and net realizable value. The clarifications are not intended to result in any changes in practice and to reduce the complexity in guidance on the subsequent measurement of inventory. This standard only applies to inventory being measured using the first-in, first-out or average cost methods of accounting for inventory. The adoption of ASU 2015-11 did not have an impact to the Company’s condensed consolidated financial statements. In March 2016, the FASB issued ASU No. 2016-05, “Derivatives and Hedging (Topic 815): Effect of Derivative Contract Novations on Existing Hedge Accounting Relationships” (“ASU 2016-05”). The amendments in ASU 2016-05 apply to all reporting entities for which there is a change in the counterparty to a derivative instrument that has been designated as a hedging instrument under Topic 815. The amendments clarify that a change in the counterparty to a derivative instrument that has been designated as the hedging instrument under Topic 815 does not, in and of itself, require de-designation of that hedging relationship provided that all other hedge accounting criteria (including those in paragraphs 815-20-35-14 through 35-18) continue to be met. The adoption of this ASU 2016-05 did not have an impact to the Company’s condensed consolidated financial statements. In March 2016, the FASB issued ASU No. 2016-07, “Investments – Equity Method and Joint Ventures (Topic 323): Simplifying the Transition to the Equity Method of Accounting” (“ASU 2016-07”). The purpose of the amendment is to eliminate the requirement that when an investment qualifies for use of the equity method as a result of an increase in the level of ownership interest or degree of influence, an investor must adjust the investment, results of operations, and retained earnings retroactively on a step-by step basis as if the equity method had been in effect during all previous periods that the investment had been held. The adoption of ASU 2016-07 did not have an impact to the Company’s condensed consolidated financial statements. In October 2016, the FASB issued ASU No. 2016-16, “Income Taxes (Topic 740)”. The purpose of ASU 2016-16 is to eliminate the exception for an intra-entity transfer of an asset other than inventory. The amendments require the recognition of the income tax consequences of an intra-entity transfer of an asset, other than inventory, when the transfer occurs. The Company has elected to early adopt ASU 2016-16 during the quarter ended March 31, 2017. The impact from the adoption was reflected in the Company’s condensed consolidated financial statements on a modified retrospective basis resulting in an increase to Accumulated deficit of $8.3 million, a decrease to Other assets of $14.8 million, an increase to Deferred taxes of $7.9 million and an increase to Accrued and other liabilities of $1.4 million. In October 2016, the FASB issued ASU No. 2016-17, “Consolidation (Topic 810)”. The purpose of ASU 2016-17 is to update the requirement of the reporting entity, in determining whether it satisfies the second characteristic of a primary beneficiary, to include all of its direct variable interests in a VIE and, on a proportionate basis, its indirect variable interests in a VIE held through related parties, including related parties that are under common control with the reporting entity. The adoption of ASU 2016-17 did not have an impact to the Company’s condensed consolidated financial statements.
Accounting Pronouncements Not Yet Adopted	In February 2016, the FASB issued ASU No. 2016-02, “Leases (Topic 842)” (“ASU 2016-02”). The purpose of the amendment is to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. New disclosures will include qualitative and quantitative requirements to provide additional information about the amounts recorded in the financial statements. Lessor accounting will remain largely unchanged from current guidance, however ASU 2016-02 will provide improvements that are intended to align lessor accounting with the lessee model and with updated revenue recognition guidance. For public entities, the amendments in ASU 2016-02 are effective for interim and annual reporting periods beginning after December 15, 2018. While the Company continues to evaluate the effect of the standard on its ongoing financial reporting, it anticipates that the adoption of ASU 2016-02 will result in a change to its financial statement disclosures. In March 2016, the FASB issued ASU No. 2016-08, “Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations” (“ASU 2016-08”). The purpose of ASU 2016-08 is to clarify the implementation of guidance on principal versus agent considerations. In April 2016, the FASB issued ASU No. 2016-10, “Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing” (“ASU 2016-10”). The purpose of ASU 2016-10 is to provide more detailed guidance in the following key areas: identifying performance obligations and licenses of intellectual property. In May 2016, the FASB issued ASU No. 2016-11, to rescind from the FASB Accounting Standards Codification certain SEC paragraphs as a result of two SEC Staff Announcements at the March 3, 2016 meeting. In May 2016, the FASB issued ASU No. 2016-12, “Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients” (“ASU 2016-12”). The purpose of ASU 2016-12 is to clarify certain narrow aspects of Topic 606 such as assessing the collectibility criterion, presentation of sales taxes and other similar taxes collected from customers, noncash consideration, contract modifications at transition, completed contracts at transition, and technical corrections. In December 2016, the FASB issued ASU No. 2016-20, “Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers”. The amendments in ASU 2016-20 represent changes to clarify the accounting standard codification, correct unintended application of guidance, or make minor improvements to the accounting standards codification that are related to Topic 606, Revenue from Contracts with Customers. For public companies, ASU 2016-08, ASU 2016-10, ASU 2016-11, ASU 2016-12 and ASU 2016-20, which are all related to Topic 606, are effective for interim and annual reporting periods beginning after December 15, 2017. The Company has performed an analysis of its contracts to determine those in scope of the standard, has performed detailed analyses of those contracts and identified its performance obligations. The Company is currently in the process of determining contract consideration and is determining the appropriate timing for revenue recognition of those performance obligations. Since many of the Company’s contracts involve variable payments tied to box-office, the Company is currently assessing an appropriate constraint to variable revenue streams in determining contract consideration under the new standard. The Company currently intends to adopt the new standard using the modified retrospective method and has begun the process of gathering historical information on its contracts in preparation for the standard’s expanded disclosure requirements. In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments” (“ASU 2016-13”). The purpose of ASU 2016-13 is to require a financial asset measured on the amortized cost basis to be presented at the net amount expected to be collected. Credit losses relating to available-for-sale debt securities should be recorded through an allowance for credit losses. For public entities, the amendments in ASU 2016-13 are effective for interim and annual reporting periods beginning after December 15, 2019. The Company is currently assessing the impact of ASU 2016-13 on its condensed consolidated financial statements. In January 2017, the FASB issued ASU No. 2017-01, “Business Combinations (Topic 805): Clarifying the Definition of a Business” (“ASU 2017-01”). The purpose of the amendment is to clarify the definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. For public entities, the amendments in ASU 2017-01 are effective for interim and annual reporting periods beginning after December 15, 2017. The adoption of this ASU 2017-01 is not expected to have a material impact to the Company’s condensed consolidated financial statements. In January 2017, the FASB issued ASU No. 2017-04, “Intangibles – Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment” (“ASU 2017-04”). The purpose of the amendment is to simplify how an entity is required to test goodwill for impairment by eliminating Step 2 from the goodwill impairment test. Step 2 measures a goodwill impairment loss by comparing the implied fair value of a reporting unit’s goodwill with the carrying amount of that goodwill. For public entities, the amendments in ASU 2017-04 are effective for interim and annual reporting periods beginning after December 15, 2019. The Company is currently assessing the impact of ASU 2017-04 on its condensed consolidated financial statements. In March 2017, the FASB issued ASU No. 2017-07, “Compensation – Retirement Benefits (Topic 715): Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost” (“ASU 2017-07”). The amendment requires the service cost component of net periodic benefit cost be presented in the same income statement line item as other employee compensation costs arising from services rendered during the period and other components of the net periodic benefit cost be presented separately from the line item that includes the service cost and outside of any subtotal of operating income. For public entities, the amendments in ASU 2017-07 are effective for interim and annual reporting periods beginning after December 15, 2017. The Company is currently assessing the impact of ASU 2017-07 on its condensed consolidated financial statements. The Company considers the applicability and impact of all recently issued FASB accounting standard codification updates. Accounting standards updates that are not noted above were assessed and determined to be not applicable or not significant to the Company’s condensed consolidated financial statements for the period ended March 31, 2017 .
Commitments and Contingencies Policy	The Company is involved in lawsuits, claims, and proceedings, including those identified below, which arise in the ordinary course of business. In accordance with the Contingencies Topic of the FASB ASC, the Company will make a provision for a liability when it is both probable that a loss has been incurred and the amount of the loss can be reasonably estimated. The Company believes it has adequate provisions for any such matters. The Company reviews these provisions in conjunction with any related provisions on assets related to the claims at least quarterly and adjusts these provisions to reflect the impacts of negotiations, settlements, rulings, advice of legal counsel and other pertinent information related to the case. Should developments in any of these matters outlined below cause a change in the Company’s determination as to an unfavorable outcome and result in the need to recognize a material provision, or, should any of these matters result in a final adverse judgment or be settled for significant amounts, they could have a material adverse effect on the Company’s results of operations, cash flows, and financial position in the period or periods in which such a change in determination, settlement or judgment occurs.
Legal Costs Policy	The Company expenses legal costs relating to its lawsuits, claims and proceedings as incurred.
Commissions Expense Policy	The Company defers direct selling costs such as sales commissions and other amounts related to its sale and sales-type lease arrangements until the related revenue is recognized.
Collaborative Arrangements Policy	In a joint revenue sharing arrangement, the Company receives a portion of a theater’s box-office and concession revenues, and in some cases a small upfront or initial payment, in exchange for placing a theater system at the theater operator’s venue. Under joint revenue sharing arrangements, the customer has the ability and the right to operate the hardware components or direct others to operate them in a manner determined by the customer. The Company’s joint revenue sharing arrangements are typically non-cancellable for 10 years or longer with renewal provisions. Title to equipment under joint revenue sharing arrangements generally does not transfer to the customer. The Company’s joint revenue sharing arrangements do not contain a guarantee of residual value at the end of the term. The customer is required to pay for executory costs such as insurance and taxes and is required to pay the Company for maintenance and extended warranty throughout the term. The customer is responsible for obtaining insurance coverage for the theater systems commencing on the date specified in the arrangement’s shipping terms and ending on the date the theater systems are delivered back to the Company.
Film Costs Policy	In a typical IMAX DMR film arrangement, the Company receives a percentage, which in recent years has averaged approximately 12.5%, of net box-office receipts, defined as gross box office receipts less applicable sales taxes, of any commercial films released in the IMAX theater network outside of Greater China from the applicable film studio for the conversion of the film to the IMAX DMR format and for access to the Company’s premium distribution platform. Within Greater China, the Company receives a lower percentage of box-office receipts for certain films. The Company does not typically hold distribution rights or the copyright to those films.
Revenue Recognition Leases	The accounting policy for the Company’s joint revenue sharing arrangements is disclosed in note 2(m) of the Company’s 2016 Form 10-K.
Films Revenue Recognition Policy	The accounting policy for the Company’s IMAX DMR arrangements is disclosed in note 2(m) of the Company’s 2016 Form 10-K. The accounting policies relating to co-produced film arrangements are disclosed in note 2(m) of the Company’s 201 6 Form 10-K.
Segment Reporting Policy	In the first quarter of 2017, modifications have been made to the CEO’s reporting package to move away from the Company’s historical two primary groups – IMAX Theater Systems and Film – and align with the way in which the CODM manages the business. The new structure is expected to assist users of the financial statements with an enhanced understanding of how management views the business, and the drivers behind the Company’s performance. C ertain of the prior period’s figures have been reclassified to conform to the current period’s presentation. The Company has identified new business as an additional reportable segment in the first quarter of 2017. The Company now has the following eight reportable segments: IMAX systems; IMAX DMR; joint revenue sharing arrangements; theater system maintenance; film distribution; film post-production; new business; and other. The Company’s reportable segments are now under four primary groups identified by nature of product sold or service provided: (1) Network Business, representing variable revenue generated by box-office results and which includes the reportable segment of IMAX DMR and contingent rent from the joint revenue sharing arrangements and IMAX systems segments; (2) Theater Business, representing revenue generated by the sale and installation of theater systems and maintenance services, primarily related to the IMAX Systems and Theater System Maintenance reportable segments, and also includes fixed hybrid revenues and upfront installation costs from the joint revenue sharing arrangements segment and after-market sales of projection system parts and 3D glasses from the other segment ; (3) New Business, which includes content licensing and distribution fees associated with the Company’s original content investments, virtual reality initiatives, IMAX Home Entertainment, and other business initiatives that are in the development and/or start-up phase, and (4) Other; which includes the film post-production and distribution segments and certain IMAX theaters that the Company owns and operates, camera rentals and other miscellaneous items from the other segment. The Company is presenting information at a disaggregated level to provide more relevant information to readers, as permitted by the standard. The accounting policies of the segments are the same as those described in note 2 to the audited consolidated financial statements included in the Company’s 2016 Form 10-K. In addition, refer to Item 2 of the Company’s Form 10-Q for additional information regarding the four primary groups mentioned above.
Fair Value of Financial Instruments Policy	Cash and cash equivalents are comprised of cash and interest-bearing investments with original maturity dates of 90 days or less. Cash and cash equivalents are recorded at cost, which approximates fair value (Level 1 input in accordance with the Fair Value Measurements Topic of the FASB ASC hierarchy) as at March 31, 2017 and December 31, 2016 , respectively. The estimated fair values of the net financed sales receivable and net investment in sales-type leases are estimated based on discounting future cash flows at currently available interest rates with comparable terms (Level 2 input in accordance with the Fair Value Measurements Topic of the FASB ASC hierarchy) as at March 31, 2017 and December 31, 2016 , respectively. The estimated fair value of the Company’s convertible loan receivable is based on discounting future cash flows at currently available interest rates with comparable terms (Level 2 input in accordance with the Fair Value Measurements Topic of the FASB ASC hierarchy) as at March 31, 2017 and December 31, 2016 , respectively. The fair value of the Company’s available-for-sale investment is determined using quoted prices in active markets (Level 2 input in accordance with the Fair Value Measurements Topic of the FASB ASC hierarchy) as at March 31, 2017 and December 31, 2016 , respectively. The fair value of foreign currency derivatives is determined using quoted prices in active markets (Level 2 input in accordance with the Fair Value Measurements Topic of the FASB ASC hierarchy) as at March 31, 2017 and December 31, 2016 , respectively. These identical instruments are traded on a closed exchange. The carrying value of borrowings under the Playa Vista Loan approximates fair value as the interest rates offered under the Playa Vista Loan are close to March 31, 2017 market rates for the Company for debt of the same remaining maturities (Level 2 input in accordance with the Fair Value Measurements Topic of the FASB ASC hierarchy) as at March 31, 2017 .
Fair Value Transfer Policy	There were no significant transfers between Level 1 and Level 2 during the three months ended March 31, 2017 or 2016 . When a determination is made to classify an asset or liability within Level 3, the determination is based upon the significance of the unobservable inputs to the overall fair value measurement.
Credit Risk Policy	The Company classifies its customers into four categories to indicate the credit quality worthiness of its financing receivables for internal purposes only: Good standing — Theater continues to be in good standing with the Company as the client’s payments and reporting are up-to-date. Credit Watch — Theater operator has begun to demonstrate a delay in payments, and has been placed on the Company's credit watch list for continued monitoring, but active communication continues with the Company. Depending on the size of outstanding balance, length of time in arrears and other factors, transactions may need to be approved by management. These financing receivables are considered to be in better condition than those receivables related to theaters in the "Pre-approved transactions" category, but not in as good of condition as those receivables in "Good standing." Pre-approved transactions only — Theater operator is demonstrating a delay in payments with little or no communication with the Company. All service or shipments to the theater must be reviewed and approved by management. These financing receivables are considered to be in better condition than those receivables related to theaters in the "All transactions suspended" category, but not in as good of condition as those receivables in "Credit Watch." Depending on the individual facts and circumstances of each customer, finance income recognition may be suspended if management believes the receivable to be impaired. All transactions suspended — Theater is severely delinquent, non-responsive or not negotiating in good faith with the Company. Once a theater is classified as “All transactions suspended” the theater is placed on nonaccrual status and all revenue recognitions related to the theater are stopped.
Condition for Company's policy to review and assess collectability on theater's past due accounts	The Company considers financing receivables to be impaired when it believes it to be probable that it will not recover the full amount of principal or interest owing under the arrangement. The Company uses its knowledge of the industry and economic trends, as well as its prior experiences to determine the amount recoverable for impaired financing receivables.
Derivatives policy	The Company is exposed to market risk from changes in foreign currency rates. A majority portion of the Company’s revenues is denominated in U.S. dollars while a substantial portion of its costs and expenses is denominated in Canadian dollars. A portion of the net U.S. dollar cash flows of the Company is periodically converted to Canadian dollars to fund Canadian dollar expenses through the spot market. In China and Japan the Company has ongoing operating expenses related to its operations in Chinese Renminbi and Japanese yen, respectively. Net cash flows are converted to and from U.S. dollars through the spot market. The Company also has cash receipts under leases denominated in Chinese Renminbi, Japanese yen, Canadian dollars and Euros which are converted to U.S. dollars through the spot market. In addition, because IMAX films generate box-office in 75 different countries, unfavourable exchange rates between applicable local currencies, and the U.S. dollar affect the Company’s reported gross box-office and revenues, further impacting the Company’s results of operations. The Company’s policy is to not use any financial instruments for trading or other speculative purposes. The Company entered into a series of foreign currency forward contracts to manage the Company’s risks associated with the volatility of foreign currencies. Certain of these foreign currency forward contracts met the criteria required for hedge accounting under the Derivatives and Hedging Topic of the FASB ASC at inception, and continue to meet hedge effectiveness tests at March 31, 2017 (the “Foreign Currency Hedges”), with settlement dates throughout 2017 and 2018 . Foreign currency derivatives are recognized and measured in the balance sheet at fair value. Changes in the fair value (gains or losses) are recognized in the condensed consolidated statements of operations except for derivatives designated and qualifying as foreign currency cash flow hedging instruments. For foreign currency cash flow hedging instruments, the effective portion of the gain or loss in a hedge of a forecasted transaction is reported in other comprehensive income and reclassified to the condensed consolidated statements of operations when the forecasted transaction occurs. Any ineffective portion is recognized immediately in the condensed consolidated statements of operations. The Company currently does not hold any derivatives which are not designated as hedging instruments
ASU 2010-20	The Company considers financing receivables with aging between 60-89 days as indications of theaters with potential collection concerns. The Company will begin to focus its review on these financing receivables and increase its discussions internally and with the theater regarding payment status. Once a theater’s aging exceeds 90 days, the Company’s policy is to review and assess collectibility on the theater’s past due accounts. Over 90 days past due is used by the Company as an indicator of potential impairment as invoices up to 90 days outstanding could be considered reasonable due to the time required for dispute resolution or for the provision of further information or supporting documentation to the customer.

Financing Receivables (Tables)

Financing Receivables (Tables)	3 Months Ended
	Mar. 31, 2017
Financing Receivables [Abstract]
Financing receivables, consisting of net investment in sales-type leases and receivables from financed sales	Financing receivables, consisting of net investment in sales-type leases and receivables from financed sales of theater systems are as follows: March 31, December 31, 2017 2016 Gross minimum lease payments receivable $ 10,119 $ 10,466 Unearned finance income (1,639) (1,710) Minimum lease payments receivable 8,480 8,756 Accumulated allowance for uncollectible amounts (672) (672) Net investment in leases 7,808 8,084 Gross financed sales receivables 151,561 154,301 Unearned finance income (38,385) (39,766) Financed sales receivables 113,176 114,535 Accumulated allowance for uncollectible amounts (494) (494) Net financed sales receivables 112,682 114,041 Total financing receivables $ 120,490 $ 122,125 Net financed sales receivables due within one year $ 22,645 $ 21,980 Net financed sales receivables due after one year $ 90,037 $ 92,061

Inventories (Tables)

Inventories (Tables)	3 Months Ended
	Mar. 31, 2017
Inventories [Abstract]
Inventories	March 31, December 31, 2017 2016 Raw materials $ 31,565 $ 28,000 Work-in-process 3,994 3,818 Finished goods 9,874 10,303 $ 45,433 $ 42,121

Property Plant and Equipment (T

Property Plant and Equipment (Tables)	3 Months Ended
	Mar. 31, 2017
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	As at March 31, 2017 Accumulated Net Book Cost Depreciation Value Equipment leased or held for use Theater system components $ 227,636 $ 93,280 $ 134,356 Camera equipment 5,990 3,879 2,111 233,626 97,159 136,467 Assets under construction 22,175 - 22,175 Other property, plant and equipment Land 8,203 - 8,203 Buildings 70,692 15,439 55,253 Office and production equipment 42,513 23,412 19,101 Leasehold improvements 10,452 3,423 7,029 131,860 42,274 89,586 $ 387,661 $ 139,433 $ 248,228 As at December 31, 2016 Accumulated Net Book Cost Depreciation Value Equipment leased or held for use Theater system components $ 224,890 $ 89,218 $ 135,672 Camera equipment 5,739 3,732 2,007 230,629 92,950 137,679 Assets under construction 18,315 - 18,315 Other property, plant and equipment Land 8,203 - 8,203 Buildings 69,861 14,877 54,984 Office and production equipment 41,128 21,935 19,193 Leasehold improvements 10,067 3,026 7,041 129,259 39,838 89,421 $ 378,203 $ 132,788 $ 245,415

Other Intangible Assets (Tables

Other Intangible Assets (Tables)	3 Months Ended
	Mar. 31, 2017
Other Intangible Assets [Abstract]
Other Intangible Assets	As at March 31, 2017 Accumulated Net Book Cost Amortization Value Patents and trademarks $ 11,578 $ 7,216 $ 4,362 Licenses and intellectual property 21,167 6,522 14,645 Other 16,686 4,587 12,099 $ 49,431 $ 18,325 $ 31,106 As at December 31, 2016 Accumulated Net Book Cost Amortization Value Patents and trademarks $ 11,395 $ 7,046 $ 4,349 Licenses and intellectual property 22,490 7,620 14,870 Other 15,352 4,155 11,197 $ 49,237 $ 18,821 $ 30,416
Other Intangible Assets - Future Amortization	As at March 31, 2017 , estimated amortization expense for each of the years ended December 31, are as follows: 2017 (nine months remaining) $ 2,774 2018 3,699 2019 3,699 2020 3,699 2021 3,699

Credit Facility and Playa Vis29

Credit Facility and Playa Vista Loan (Tables)	3 Months Ended
	Mar. 31, 2017
Credit Facility and Playa Vista Loan [Abstract]
Bank indebtedness	Bank indebtedness includes the following: March 31, December 31, 2017 2016 Playa Vista Loan $ 27,167 $ 27,667 Deferred charges on debt financing (341) (351) $ 26,826 $ 27,316
Construction loan principal payments	In accordance with the loan agreement, the Company is obligated to make payments on the principal of the loan as follows: 2017 (nine months remaining) $ 1,500 2018 2,000 2019 2,000 2020 2,000 2021 2,000 Thereafter 17,667 $ 27,167

Condensed Consolidated Statem30

Condensed Consolidated Statements of Cash Flows Supplemental Information (Tables)	3 Months Ended
	Mar. 31, 2017
Condensed Consolidated Statements of Cash Flows Supplemental Information [Abstract]
Changes in other non-cash operating assets and liabilities	Three Months Ended March 31, 2017 2016 Decrease (increase) in: Accounts receivable $ 161 $ 6,070 Financing receivables 1,763 (1,748) Inventories (3,312) (5,994) Prepaid expenses (1,421) (2,345) Commissions and other deferred selling expenses (228) 34 Insurance recoveries (96) 132 Other assets 100 (441) Increase (decrease) in: Accounts payable (6,041) (2,470) Accrued and other liabilities (18,825) (12,023) Deferred revenue 10,619 (2,998) $ (17,280) $ (21,783)
Cash payments	Three Months Ended March 31, 2017 2016 Income taxes $ 7,270 $ 12,051 Interest $ 190 $ 180
Summary of depreciation and amortization	Three Months Ended March 31, 2017 2016 Film assets $ 3,805 $ 3,356 Property, plant and equipment Joint revenue sharing arrangements 4,246 3,738 Other property, plant and equipment 2,760 2,326 Other intangible assets 926 672 Other assets 220 205 Deferred financing costs 131 141 $ 12,088 $ 10,438
Write downs, net of recoveries	Three Months Ended March 31, 2017 2016 Accounts receivable $ 185 $ 126 Inventories - 184 Film assets (1) 3,416 - Property, plant and equipment (2) 409 329 Other intangible assets - 9 $ 4,010 $ 648

Income Taxes (Tables)

Income Taxes (Tables)	3 Months Ended
	Mar. 31, 2017
Income Taxes [Abstract]
Income tax effect related to other comprehensive loss	Three Months Ended March 31, 2017 2016 Unrealized change in cash flow hedging instruments $ (82) $ (574) Realized change in cash flow hedging instruments upon settlement (75) (332) Amortization of actuarial loss on postretirement benefit plan - (5) $ (157) $ (911)

Capital Stock (Tables)

Capital Stock (Tables)	3 Months Ended
	Mar. 31, 2017
Capital Stock [Abstract]
Weighted average fair value of common share granted to employees and directors	The following assumptions were used to estimate the average fair value of the stock options: Three Months Ended March 31, 2017 2016 Average risk-free interest rate 2.40% 1.72% Expected option life (in years) 4.71 - 5.83 4.79 - 4.88 Expected volatility 30% 30% Dividend yield 0% 0%
Option activity under the Stock Option Plan and the IMAX LTIP	The following table summarizes certain information in respect of option activity under the SOP and IMAX LTIP for the three month periods ended March 31 : Weighted Average Exercise Number of Shares Price Per Share 2017 2016 2017 2016 Options outstanding, beginning of period 5,190,542 4,805,244 $ 28.35 $ 27.03 Granted 679,030 323,925 32.16 31.85 Exercised (584,589) (43,750) 22.38 16.91 Forfeited (16,380) (2,042) 31.69 31.85 Options outstanding, end of period 5,268,603 5,083,377 29.49 27.42 Options exercisable, end of period 3,945,034 3,507,573 28.68 26.52
Restricted Stock Units activity under the IMAX LTIP	The following table summarizes certain information in respect of RSU activity under the IMAX LTIP for the three months ended March 31 : Number of Awards Weighted Average Grant Date Fair Value Per Share 2017 2016 2017 2016 RSUs outstanding, beginning of period 1,124,180 973,637 $ 33.01 $ 32.27 Granted 373,540 351,584 32.45 31.85 Vested and settled (201,793) (190,298) 31.25 29.47 Forfeited (20,506) (3,092) 32.31 32.43 RSUs outstanding, end of period 1,275,421 1,131,831 33.13 32.61
Basic and diluted per-share computations	Reconciliations of the numerator and denominator of the basic and diluted per-share computations are comprised of the following: Three Months Ended March 31, 2017 2016 Net income applicable to common shareholders $ 75 $ 11,302 Weighted average number of common shares (000's): Issued and outstanding, beginning of period 66,160 69,673 Weighted average number of shares issued (repurchased) during the period 203 (294) Weighted average number of shares used in computing basic income per share 66,363 69,379 Assumed exercise of stock options and RSUs, net of shares assumed repurchased 817 741 Weighted average number of shares used in computing diluted income per share 67,180 70,120
Movement of Shareholders' Equity	The following summarizes the movement of Shareholders’ Equity attributable to common shareholders for the three months ended March 31, 2017 : Balance as at December 31, 2016 $ 562,012 Net income attributable to common shareholders 75 Retrospective adjustment related to intra-entity transfers (notes 2 and 11) (8,314) Adjustments to capital stock: Cash received from the issuance of common shares 13,082 Issuance of common shares for vested RSUs 273 Fair value of stock options exercised at the grant date 3,270 Share held in treasury 1,160 Adjustments to other equity: Employee stock options granted 1,596 Non-employee stock options granted and vested 17 Fair value of stock options exercised at the grant date (3,270) RSUs granted 3,554 RSUs vested (6,506) Stock exercised from treasury shares (7,025) Adjustments to accumulated other comprehensive loss: Unrealized net gain from cash flow hedging instruments 313 Realization of cash flow hedging net loss upon settlement 285 Foreign currency translation adjustments 312 Tax effect of movement in other comprehensive income (157) Balance as at March 31, 2017 $ 560,677

Segmented Information (Tables)

Segmented Information (Tables)	3 Months Ended
	Mar. 31, 2017
Segmented Information [Abstract]
Inter-segment revenue	Three Months Ended March 31, 2017 2016 Revenue (1) Network business IMAX DMR $ 23,408 $ 29,805 Joint revenue sharing arrangements – contingent rent 15,233 21,315 IMAX systems – contingent rent 688 1,187 39,329 52,307 Theater business IMAX systems 9,527 20,674 Joint revenue sharing arrangements – fixed fees 470 2,070 Theater system maintenance 11,045 9,826 Other theater 2,165 2,487 23,207 35,057 New business 1,280 - Other Film post-production 3,072 2,407 Film distribution 512 363 Other 1,257 1,994 4,841 4,764 Total $ 68,657 $ 92,128 Gross Margin Network business IMAX DMR (2) $ 17,467 $ 22,823 Joint revenue sharing arrangements – contingent rent (2) 10,250 17,487 IMAX systems – contingent rent 688 1,187 28,405 41,497 Theater business IMAX systems (2) 5,741 6,648 Joint revenue sharing arrangements – fixed fees (2) 88 504 Theater system maintenance 4,249 3,439 Other theater 430 (32) 10,508 10,559 New business (337) (225) Other Film post-production 1,101 1,249 Film distribution (2) (3,764) (679) Other (142) (225) (2,805) 345 Total $ 35,771 $ 52,176
Geographic Information	Three Months Ended March 31, 2017 2016 Revenue United States $ 25,198 $ 35,544 Canada 3,282 7,077 Greater China 18,590 24,939 Asia (excluding Greater China) 8,429 5,559 Western Europe 5,813 11,486 Russia & the CIS 3,183 1,692 Latin America 1,654 3,527 Rest of the World 2,508 2,304 Total $ 68,657 $ 92,128

Employees Pension and Postret34

Employees Pension and Postretirement Benefits (Tables)	3 Months Ended
	Mar. 31, 2017
Defined Benefit Plan Disclosure [Line Items]
Amounts accrued	March 31, December 31, 2017 2016 Projected benefit obligation: Obligation, beginning of period $ 19,580 $ 19,478 Interest cost 107 261 Actuarial gain - (159) Obligation, end of period and unfunded status $ 19,687 $ 19,580
SERP Benefits [Member]
Defined Benefit Plan Disclosure [Line Items]
Pension Expense	Three Months Ended March 31, 2017 2016 Interest cost $ 107 $ 65 Pension expense $ 107 $ 65
Schedule of expected benefit payments	2017 (nine months remaining) $ - 2018 - 2019 - 2020 21,115 2021 - Thereafter - $ 21,115
Postretirement Benefits Executives [Member]
Defined Benefit Plan Disclosure [Line Items]
Schedule of expected benefit payments	2017 (nine months remaining) $ 21 2018 24 2019 26 2020 33 2021 36 Thereafter 514 Total $ 654
Postretirement Benefits Canadian Employees [Member]
Defined Benefit Plan Disclosure [Line Items]
Schedule of expected benefit payments	2017 (nine months remaining) $ 92 2018 99 2019 105 2020 108 2021 110 Thereafter 1,244 Total $ 1,758

Financial Instruments (Tables)

Financial Instruments (Tables)	3 Months Ended
	Mar. 31, 2017
Financial Instruments [Abstract]
Fair Value of Financial Instruments	The carrying values of the Company’s cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities due within one year approximate fair values due to the short-term maturity of these instruments. The Company’s other financial instruments are comprised of the following: As at March 31, 2017 As at December 31, 2016 Carrying Estimated Carrying Estimated Amount Fair Value Amount Fair Value Cash and cash equivalents $ 190,481 $ 190,481 $ 204,759 $ 204,759 Net financed sales receivable $ 112,682 $ 113,792 $ 114,041 $ 115,014 Net investment in sales-type leases $ 7,808 $ 8,163 $ 8,084 $ 8,372 Convertible loan receivable $ 1,000 $ 1,000 $ 1,000 $ 1,000 Available-for-sale investment $ 1,000 $ 1,010 $ 1,000 $ 1,007 Foreign exchange contracts — designated forwards $ 302 $ 302 $ (296) $ (296) Borrowings under the Playa Vista Loan $ (27,167) $ (27,167) $ (27,667) $ (27,667)
Recorded Investment in Financing Receivables	The following table discloses the recorded investment in financing receivables by credit quality indicator: As at March 31, 2017 As at December 31, 2016 Minimum Financed Minimum Financed Lease Sales Lease Sales Payments Receivables Total Payments Receivables Total In good standing $ 7,465 $ 110,249 $ 117,714 $ 7,741 $ 111,568 $ 119,309 Credit Watch - 1,683 1,683 - 1,514 1,514 Pre-approved transactions - 633 633 - 842 842 Transactions suspended 1,015 611 1,626 1,015 611 1,626 $ 8,480 $ 113,176 $ 121,656 $ 8,756 $ 114,535 $ 123,291
Investment In Financing Receivables On Nonaccrual Status	The Company’s investment in financing receivables on nonaccrual status is as follows: As at March 31, 2017 As at December 31, 2016 Recorded Related Recorded Related Investment Allowance Investment Allowance Net investment in leases $ 1,015 $ (672) $ 1,015 $ (672) Net financed sales receivables 611 (494) 611 (494) Total $ 1,626 $ (1,166) $ 1,626 $ (1,166)
Aging of Financing Receivables	The Company’s aged financing receivables are as follows: As at March 31, 2017 Related Recorded Accrued Billed Unbilled Total Investment and 30-89 Financing Recorded Recorded Related Net of Current Days 90+ Days Receivables Investment Investment Allowances Allowances Net investment in leases $ 41 $ 94 $ 763 $ 898 $ 7,582 $ 8,480 $ (672) $ 7,808 Net financed sales receivables 1,884 2,379 2,879 7,142 106,035 113,176 (494) 112,682 Total $ 1,925 $ 2,473 $ 3,642 $ 8,040 $ 113,617 $ 121,656 $ (1,166) $ 120,490 As at December 31, 2016 Related Recorded Accrued Billed Unbilled Total Investment and 30-89 Financing Recorded Recorded Related Net of Current Days 90+ Days Receivables Investment Investment Allowances Allowances Net investment in leases $ 28 $ 159 $ 781 $ 968 $ 7,788 $ 8,756 $ (672) $ 8,084 Net financed sales receivables 2,393 1,724 2,368 6,485 108,050 114,535 (494) 114,041 Total $ 2,421 $ 1,883 $ 3,149 $ 7,453 $ 115,838 $ 123,291 $ (1,166) $ 122,125
Financing receivables continues to accrue finance income	The Company’s recorded investment in past due financing receivables for which the Company continues to accrue finance income is as follows: As at March 31, 2017 Related Recorded Accrued Billed Unbilled Investment and Financing Recorded Related Past Due Current 30-89 Days 90+ Days Receivables Investment Allowance and Accruing Net investment in leases $ 38 $ 61 $ 293 $ 392 $ 2,237 $ - $ 2,629 Net financed sales receivables 146 968 2,280 3,394 25,876 - 29,270 Total $ 184 $ 1,029 $ 2,573 $ 3,786 $ 28,113 $ - $ 31,899 As at December 31, 2016 Related Recorded Accrued Billed Unbilled Investment and Financing Recorded Related Past Due Current 30-89 Days 90+ Days Receivables Investment Allowance and Accruing Net investment in leases $ - $ 54 $ 244 $ 298 $ 1,646 $ - $ 1,944 Net financed sales receivables 284 634 1,854 2,772 20,147 - 22,919 Total $ 284 $ 688 $ 2,098 $ 3,070 $ 21,793 $ - $ 24,863
Impaired financing receivables	The following table discloses information regarding the Company’s impaired financing receivables: For the Three Months Ended March 31, 2017 Average Interest Recorded Unpaid Related Recorded Income Investment Principal Allowance Investment Recognized Recorded investment for which there is a related allowance: Net financed sales receivables $ 525 $ 75 $ (494) $ 525 $ - Recorded investment for which there is no related allowance: Net financed sales receivables - - - - - Total recorded investment in impaired loans: Net financed sales receivables $ 525 $ 75 $ (494) $ 525 $ - For the Three Months Ended March 31, 2016 Average Interest Recorded Unpaid Related Recorded Income Investment Principal Allowance Investment Recognized Recorded investment for which there is a related allowance: Net financed sales receivables $ 748 $ 414 $ (643) $ 748 $ - Recorded investment for which there is no related allowance: Net financed sales receivables - - - - - Total recorded investment in impaired loans: Net financed sales receivables $ 748 $ 414 $ (643) $ 748 $ -
Allowance for credit losses and investment in financing receivables	The Company’s activity in the allowance for credit losses for the period and the Company’s recorded investment in financing receivables are as follows: Three Months Ended March 31, 2017 Three Months Ended March 31, 2016 Net Investment Net Financed Net Investment Net Financed in Leases Sales Receivables in Leases Sales Receivables Allowance for credit losses: Beginning balance $ 672 $ 494 $ 672 $ 568 Charge-offs - - - - Recoveries - - - - Provision - - - 75 Ending balance $ 672 $ 494 $ 672 $ 643 Ending balance: individually evaluated for impairment $ 672 $ 494 $ 672 $ 643 Financing receivables: Ending balance: individually evaluated for impairment $ 8,480 $ 113,176 $ 10,577 $ 110,387
Notional amount of derivative	Notional value of foreign exchange contracts: March 31, December 31, 2017 2016 Derivatives designated as hedging instruments: Foreign exchange contracts — Forwards $ 39,802 $ 37,825
Fair value of foreign exchange contracts	Fair value of derivatives in foreign exchange contracts: March 31, December 31, Balance Sheet Location 2017 2016 Derivatives designated as hedging instruments: Foreign exchange contracts — Forwards Other assets $ 604 $ 480 Accrued and other liabilities (302) (776) $ 302 $ (296)
Derivatives in Foreign Currency Hedging relationships	Three Months Ended March 31, 2017 2016 Foreign exchange contracts — Forwards Derivative Gain Recognized in OCI (Effective Portion) $ 313 $ 2,207 Location of Derivative Loss Reclassified from AOCI Three Months Ended March 31, into Income (Effective Portion) 2017 2016 Foreign exchange contracts — Forwards Selling, general and administrative expenses $ (285) $ (1,277) Three Months Ended March 31, 2017 2016 Foreign exchange contracts - Forwards Derivative Loss Recognized In and Out of OCI (Effective Portion) $ (47) $ -

Non-Controlling Interests (Tabl

Non-Controlling Interests (Tables)	3 Months Ended
	Mar. 31, 2017
IMAX China Noncontrolling Interest
Non-controlling Interests
Non-controlling Interests	Balance as at December 31, 2016 $ 59,562 Net income 1,463 Other comprehensive loss 146 Balance as at March 31, 2017 $ 61,171
Other Noncontrolling Interest [Member]
Non-controlling Interests
Non-controlling Interests	Balance as at December 31, 2016 $ 4,980 Net loss (2,425) Balance as at March 31, 2017 $ 2,555

Basis of Presentation (Details)

Basis of Presentation (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016
Basis of Presentation (Textuals) [Abstract]
Number Of Variable Interest Entities	9
Number Of Variable Interest Entities Primary Beneficiary	4
Number Of Variable Interest Entities Not A Primary Beneficiary	5
Variable interest entity, non-consolidated, Assets	$ 0.4
Variable interest entity, non-consolidated, Liabilities	0.4
Variable Interest Entity, Primary Beneficiary [Member]
Basis of Presentation (Textuals) [Abstract]
Variable interest entity, consolidated, Assets	5.8		$ 10.3
Variable interest entity, consolidated, Liabilities	6.5		6.4
Variable Interest Entity, Not Primary Beneficiary [Member]
Basis of Presentation (Textuals) [Abstract]
Variable interest entity, non-consolidated, Assets	0.4		0.4
Variable interest entity, non-consolidated, Liabilities	0.4		0.4
Earnings of the investees	0	$ 0
Carrying value of film production company VIEs	0		0
Loss exposure	$ 0		$ 0

New Accounting Standards And 38

New Accounting Standards And Accounting Changes (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2017USD ($)
New Accounting Pronouncements and Changes in Accounting Principles
Impact on accumulated deficit due to adoption of ASU 2016-16	$ 8,314
Impact on other assets due to adoption of ASU 2016-16	(14,800)
Impact on deferred taxes due to adoption of ASU 2016-16	7,900
Impact on accrued and other liabilities due to adoption of ASU 2016-16	$ 1,400

Financing Receivables (Details)

Financing Receivables (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Financing receivables, consisting of net investment in sales-type leases and receivables from financed sales
Gross minimum lease payments receivable	$ 10,119	$ 10,466
Unearned finance income	(1,639)	(1,710)
Minimum lease payments receivable	8,480	8,756
Accumulated allowance for uncollectible amounts	(672)	(672)
Net investment in leases	7,808	8,084
Gross financed sales receivables	151,561	154,301
Unearned finance income	(38,385)	(39,766)
Financed sales receivables	113,176	114,535
Accumulated allowance for uncollectible amounts	(494)	(494)
Net financed sales receivables	112,682	114,041
Total financing receivables	120,490	122,125
Net financed sales receivables due within one year	22,645	21,980
Net financed sales receivables due after one year	$ 90,037	$ 92,061

Inventories (Details)

Inventories (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Inventories
Raw materials	$ 31,565	$ 28,000
Work-in-process	3,994	3,818
Finished goods	9,874	10,303
Total	$ 45,433	$ 42,121

Property Plant and Equipment (D

Property Plant and Equipment (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Property, plant and equipment
Cost	$ 387,661	$ 378,203
Accumulated Depreciation	139,433	132,788
Net Book Value	248,228	245,415
Equipment leased or held for use [Member]
Property, plant and equipment
Cost	233,626	230,629
Accumulated Depreciation	97,159	92,950
Net Book Value	136,467	137,679
Theater System Components [Member]
Property, plant and equipment
Cost	227,636	224,890
Accumulated Depreciation	93,280	89,218
Net Book Value	134,356	135,672
Camera Equipment [Member]
Property, plant and equipment
Cost	5,990	5,739
Accumulated Depreciation	3,879	3,732
Net Book Value	2,111	2,007
Assets Under Construction [Member]
Property, plant and equipment
Cost	22,175	18,315
Accumulated Depreciation	0	0
Net Book Value	22,175	18,315
Other property, plant and equipment [Member]
Property, plant and equipment
Cost	131,860	129,259
Accumulated Depreciation	42,274	39,838
Net Book Value	89,586	89,421
Land [Member]
Property, plant and equipment
Cost	8,203	8,203
Accumulated Depreciation	0	0
Net Book Value	8,203	8,203
Buildings [Member]
Property, plant and equipment
Cost	70,692	69,861
Accumulated Depreciation	15,439	14,877
Net Book Value	55,253	54,984
Office and Production Equipment [Member]
Property, plant and equipment
Cost	42,513	41,128
Accumulated Depreciation	23,412	21,935
Net Book Value	19,101	19,193
Leasehold Improvements [Member]
Property, plant and equipment
Cost	10,452	10,067
Accumulated Depreciation	3,423	3,026
Net Book Value	$ 7,029	$ 7,041

Other Intangible Assets (Detail

Other Intangible Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Other Intangible Assets
Other Intangible Assets, Cost	$ 49,431	$ 49,237
Other Intangible Assets, Accumulated Amortization	18,325	18,821
Other Intangible Assets, Net Book Value	31,106	30,416
Patents and Trademarks [Member]
Other Intangible Assets
Other Intangible Assets, Cost	11,578	11,395
Other Intangible Assets, Accumulated Amortization	7,216	7,046
Other Intangible Assets, Net Book Value	4,362	4,349
Licenses and Intellectual Property [Member]
Other Intangible Assets
Other Intangible Assets, Cost	21,167	22,490
Other Intangible Assets, Accumulated Amortization	6,522	7,620
Other Intangible Assets, Net Book Value	14,645	14,870
Other [Member]
Other Intangible Assets
Other Intangible Assets, Cost	16,686	15,352
Other Intangible Assets, Accumulated Amortization	4,587	4,155
Other Intangible Assets, Net Book Value	$ 12,099	$ 11,197

Credit Facility and Playa Vis43

Credit Facility and Playa Vista Loan (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Bank indebtedness [Line Items]
Total bank indebtedness	$ 26,826	$ 27,316
Playa Vista Loan [Member]
Bank indebtedness [Line Items]
Playa Vista Loan	27,167	27,667
Deferred charges on debt financing	(341)	(351)
Total bank indebtedness	26,826	27,316
Playa Vista loan principal payments
2017 (nine months remaining)	1,500
2,018	2,000
2,019	2,000
2,020	2,000
2,021	2,000
Thereafter	17,667
Playa Vista Loan	$ 27,167	$ 27,667

Condensed Consolidated Statem44

Condensed Consolidated Statement of Operations Supplemental Information (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2017USD ($)yrFilmexhibitorTheaters	Mar. 31, 2016USD ($)Film
Selling Expenses
Deferred direct selling costs and direct advertising and marketing included in costs and expenses applicable to revenues-equipment and product sales	$ 400	$ 700
Film exploitation costs, including advertising and marketing included in costs and expenses applicable to revenues-services	2,400	$ 3,000
Commissions recognized as cost and expenses included in costs and expenses applicable to revenues-rentals		less than
Commissions recognized as cost and expenses included in costs and expenses applicable to revenues-rentals	100	$ (100)
Direct advertising and marketing costs included in costs and expenses applicable to revenues-rentals		less than
Direct advertising and marketing costs included in costs and expenses applicable to revenues-rentals	$ 300	$ 100
Foreign Exchange
Foreign exchange translation loss (gain)	less than
Foreign exchange translation loss (gain)	$ 100	(500)
Collaborative Arrangements
Total number of exhibitors under joint revenue sharing agreements | exhibitor	46
Total number of theater systems under joint revenue sharing agreements | Theaters	997
Total number of operating theaters under joint revenue sharing agreement | Theaters	649
Amounts attributable to transactions arising between the company and its customers under joint revenue sharing arrangements	$ 15,700	$ 23,400
Average percentage of the box-office receipts of the film for recovering digital re-mastering cost	12.50%
IMAX DMR films exhibited in the period | Film	18	17
Amounts attributable to transactions arising between the company and its customers under IMAX DMR arrangements	$ 23,408	$ 29,805
Number of significant co-produced film arrangement | Film	1
Number of other co-produced film arrangements | Film	4
Variable interest entity, non-consolidated, Assets	$ 400
Variable interest entity, non-consolidated, Liabilities	400
Amounts attributable to transactions between the company and other parties involved in the production of films included in cost and expense	$ 500	$ 200
Minimum [Member]
Collaborative Arrangements
Non-cancellable term of joint revenue sharing arrangements | yr	10
Maximum [Member]
Collaborative Arrangements
Non-cancellable term of joint revenue sharing arrangements	longer

Condensed Consolidated Statem45

Condensed Consolidated Statements of Cash Flows Supplemental Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Decrease (increase) in:
Accounts receivable	$ 161	$ 6,070
Financing receivables	1,763	(1,748)
Inventories	(3,312)	(5,994)
Prepaid expenses	(1,421)	(2,345)
Commissions and other deferred selling expenses	(228)	34
Insurance recoveries	(96)	132
Other assets	100	(441)
Increase (decrease) in:
Accounts payable	(6,041)	(2,470)
Accrued and other Liabilities	(18,825)	(12,023)
Deferred revenue	10,619	(2,998)
Changes in other non-cash operating assets and liabilities	(17,280)	(21,783)
Cash payments
Income taxes	7,270	12,051
Interest	$ 190	$ 180

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Unrealized change in cash flow hedging instruments	$ (82)	$ (574)
Realized change in cash flow hedging instruments upon settlement	(75)	(332)
Amortization of actuarial loss on postretirement benefit plan	0	(5)
Income tax effect on other comprehensive income	$ (157)	$ (911)

Capital Stock (Details)

Capital Stock (Details) - Employee Stock Option [Member]	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Weighted average fair value of common share granted to employees and directors
Average risk-free interest rate	2.40%	1.72%
Expected volatility	30.00%	30.00%
Dividend yield	0.00%	0.00%
Minimum [Member]
Weighted average fair value of common share granted to employees and directors
Expected option life (in years)	4 years 8 months 16 days	4 years 9 months 14 days
Maximum [Member]
Weighted average fair value of common share granted to employees and directors
Expected option life (in years)	5 years 9 months 29 days	4 years 10 months 17 days

Segmented Information (Details)

Segmented Information (Details) - USD ($) $ in Thousands		3 Months Ended
		Mar. 31, 2017	Mar. 31, 2016
Revenues
Revenues		$ 68,657	$ 92,128
Gross margins
Gross margins		35,771	52,176
Network Business Total [Member]
Revenues
Revenues	[1]	39,329	52,307
Gross margins
Gross margins		28,405	41,497
IMAX DMR [Member]
Revenues
Revenues	[1]	23,408	29,805
Gross margins
Gross margins	[2]	17,467	22,823
Joint revenue sharing arrangements - contingent rent [Member]
Revenues
Revenues	[1]	15,233	21,315
Gross margins
Gross margins	[2]	10,250	17,487
IMAX systems - contingent rent [Member]
Revenues
Revenues	[1]	688	1,187
Gross margins
Gross margins		688	1,187
Theater Business Total [Member]
Revenues
Revenues	[1]	23,207	35,057
Gross margins
Gross margins		10,508	10,559
IMAX Systems [Member]
Revenues
Revenues	[1]	9,527	20,674
Gross margins
Gross margins	[2]	5,741	6,648
Joint revenue sharing arrangements - fixed fees [Member]
Revenues
Revenues	[1]	470	2,070
Gross margins
Gross margins	[2]	88	504
Theater system maintenance [Member]
Revenues
Revenues	[1]	11,045	9,826
Gross margins
Gross margins		4,249	3,439
Other theater [Member]
Revenues
Revenues	[1]	2,165	2,487
Gross margins
Gross margins		430	(32)
New Business [Member]
Revenues
Revenues	[1]	1,280	0
Gross margins
Gross margins		(337)	(225)
Other Total [Member]
Revenues
Revenues	[1]	4,841	4,764
Gross margins
Gross margins		(2,805)	345
Film post-production [Member]
Revenues
Revenues	[1]	3,072	2,407
Gross margins
Gross margins		1,101	1,249
Film distribution [Member]
Revenues
Revenues	[1]	512	363
Gross margins
Gross margins	[2]	(3,764)	(679)
Other [Member]
Revenues
Revenues	[1]	1,257	1,994
Gross margins
Gross margins		$ (142)	$ (225)
[1]	The Company’s largest customer represented 17.2% of total revenues for the three months ended March 31, 2017 (2016 — 16.0%).
[2]	IMAX DMR segment margins include marketing costs of $2.6 million for the three months ended March 31, 2017 (2016 — $2.3 million). Joint revenue sharing arrangements segment margins include advertising, marketing and commission costs of $0.4 million for the three months ended March 31, 2017 (2016 — $0.1 million). IMAX systems segment margins include marketing and commission costs of $0.4 million for the three months ended March 31, 2017 (2016 — $0.5 million). Film distribution segment margins include a marketing recovery of $0.2 million for the three months ended March 31, 2017 (2016 — expense of $0.7 million).

Employees Pension and Postret49

Employees Pension and Postretirement Benefits (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016
Amounts Accrued
Interest cost	$ 107	$ 65
Pension Expense
Interest cost	107	65
Pension expense	107	65
Pension Plans, Defined Benefit [Member]
Amounts Accrued
Obligation, beginning of period	19,580	19,478	$ 19,478
Interest cost	107	65	261
Actuarial gain	0		(159)
Obligation, end of period and unfunded status	19,687		19,580
Pension Expense
Interest cost	107	65	$ 261
Pension expense	$ 107	$ 65

Financial Instruments (Details)

Financial Instruments (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016	Mar. 31, 2016	Dec. 31, 2015
Other Financial Instrument
Cash and cash equivalents	$ 190,481	$ 204,759	$ 259,752	$ 317,449
Net financed sales receivable	112,682	114,041
Net investment in sales-type leases	7,808	8,084
Convertible loan receivable		1,000
Available-for-sale preferred shares	1,500
Foreign exchange contracts - designated forwards	302	(296)
Carrying (Reported) Amount, Fair Value Disclosure [Member] | Fair Value, Inputs, Level 1 [Member]
Other Financial Instrument
Cash and cash equivalents	190,481	204,759
Carrying (Reported) Amount, Fair Value Disclosure [Member] | Fair Value, Inputs, Level 2 [Member]
Other Financial Instrument
Net financed sales receivable	112,682	114,041
Net investment in sales-type leases	7,808	8,084
Convertible loan receivable	1,000	1,000
Available-for-sale investment	1,000	1,000
Borrowings under the Playa Vista Loan	(27,167)	(27,667)
Carrying (Reported) Amount, Fair Value Disclosure [Member] | Designated as Hedging Instrument [Member] | Fair Value, Inputs, Level 2 [Member]
Other Financial Instrument
Foreign exchange contracts - designated forwards	302	(296)
Estimate of Fair Value, Fair Value Disclosure [Member] | Fair Value, Inputs, Level 1 [Member]
Other Financial Instrument
Cash and cash equivalents	190,481	204,759
Estimate of Fair Value, Fair Value Disclosure [Member] | Fair Value, Inputs, Level 2 [Member]
Other Financial Instrument
Net financed sales receivable	113,792	115,014
Net investment in sales-type leases	8,163	8,372
Convertible loan receivable	1,000	1,000
Available-for-sale investment	1,010	1,007
Borrowings under the Playa Vista Loan	(27,167)	(27,667)
Estimate of Fair Value, Fair Value Disclosure [Member] | Designated as Hedging Instrument [Member] | Fair Value, Inputs, Level 2 [Member]
Other Financial Instrument
Foreign exchange contracts - designated forwards	$ 302	$ (296)

Non-Controlling Interests (Deta

Non-Controlling Interests (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2015
Non-controlling Interests
Net income (loss)	$ (962)	$ 2,650
IMAX China Noncontrolling Interest
Non-controlling Interests
Balance as at December 31, 2016	59,562
Net income (loss)	1,463
Other comprehensive loss	146
Dividends paid to non-controlling interests			$ (9,500)
Balance as at March 31, 2017	61,171
Other Noncontrolling Interest [Member]
Non-controlling Interests
Balance as at December 31, 2016	4,980
Net income (loss)	(2,425)
Balance as at March 31, 2017	$ 2,555

Financing Receivables (Details

Financing Receivables (Details Textuals)	Mar. 31, 2017	Dec. 31, 2016
Financing Receivables (Textuals) [Abstract]
Financed sale receivables, Weighted average effective interest rate	9.30%	9.30%

Inventories (Details Textuals)

Inventories (Details Textuals) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016
Inventories (Textuals) [Abstract]
Finished goods inventory with title passed to customer	$ 3,300		$ 2,300
Write-downs for excess and obsolete inventory	$ 0	$ 184

Other Intangible Assets (Deta54

Other Intangible Assets (Details 1) $ in Thousands	Mar. 31, 2017USD ($)
Other Intangible Assets [Abstract]
2017 (nine months remaining)	$ 2,774
2,018	3,699
2,019	3,699
2,020	3,699
2,021	$ 3,699

Other Intangible Assets (Deta55

Other Intangible Assets (Details Textuals) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Other Intangible Assets (Textuals) [Abstract]
Other Intangible Asset, comprised mainly of ERP System	$ 16.7
Acquisition of other intangible assets, cost	$ 1.6
Weighted average amortization period for additions to other intangible assets	P10Y
Costs incurred to renew or extend the term of acquired other intangible assets	$ 0.1	$ 0.1

Credit Facility and Playa Vis56

Credit Facility and Playa Vista Loan (Details Textuals) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016	Mar. 03, 2015
Playa Vista Loan [Member]
Credit Facility and Playa Vista Loan (Textuals) [Abstract]
Maximum borrowing capacity	$ 30,000
Amounts Drawn	$ 27,167		$ 27,667
Interest rate description	variable rate per annum at 2.0% above the 30-day LIBOR rate
Effective interest rate	2.85%	2.43%
Maturity date	Oct. 19, 2025
Term of loan	120 months
Playa Vista Loan - Payment Terms	PV Borrower will be required to make monthly payments of combined principal and interest over a 10-year term with a lump sum payment at the end of year 10. The Playa Vista Loan is being amortized over 15 years. The Playa Vista Loan will be fully due and payable on October 19, 2025.
Playa Vista Loan - Security	The Playa Vista Loan is secured by a deed of trust from PV Borrower in favor of Wells Fargo, granting a first lien on and security interest in the Playa Vista property and the Playa Vista Project, including all improvements to the constructed thereon, and other documents evidencing and securing the loan (the "Loan Documents").
Credit Facility [Member]
Credit Facility and Playa Vista Loan (Textuals) [Abstract]
Credit Facility Maturity Date	Mar. 3, 2020
Maximum borrowing capacity				$ 200,000
Remaining Borrowing Capacity	$ 200,000		200,000
Amounts Drawn	0		0
Letters of credit and advance payment guarantees	$ 0		0
Line of credit facility covenant terms	On February 22, 2016, the Company amended the terms of the Credit Agreement to increase the general restricted payment basket thereunder (which covers, among other things, the repurchase of shares) from $150 million to $350 million in the aggregate after the amendment date.
Compliance with covenants	The Company was in compliance with all of its requirements at March 31, 2017.
Wells Fargo Foreign Exchange Facility [Member]
Credit Facility and Playa Vista Loan (Textuals) [Abstract]
Settlement risk on its foreign currency forward contracts	$ 0
Notional Amount of arrangements entered into	39,802
Bank of Montreal Facilities [Member]
Credit Facility and Playa Vista Loan (Textuals) [Abstract]
Remaining Borrowing Capacity	10,000		10,000
Letters of credit and advance payment guarantees	$ 0		$ 100

Contingencies and Guarantees (D

Contingencies and Guarantees (Details Textuals) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended	25 Months Ended	51 Months Ended	95 Months Ended
	Mar. 31, 2017	Dec. 31, 2016	Dec. 14, 2015	Mar. 27, 2008	Dec. 02, 2011
Final Award in favor of company				Amount of $11.3 million plus an additional $2,512 each day in interest from October 1, 2007 until the date the award is paid	$30,000 to cover the costs of the application
Damages sought			$ 10,400
Counterclaim sought			$ 24,000
Duties and taxes paid related to customs audit	$ 2,950
Underpayment of the freight and insurance portion of the customs duties and taxes related to the customs audit	100
Financial Guarantees	$ 0
Product Warranty Accrual	less than	less than
Product Warranty Accrual	$ 100	$ 100
Indemnification of its directors/officers	$ 0	$ 0
Other Indemnification	0

Condensed Consolidated Statem58

Condensed Consolidated Statements of Cash Flows Supplemental Information (Details 1) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Summary of Depreciation and amortization
Film assets	$ 3,805	$ 3,356
Property, plant and equipment
Joint revenue sharing arrangements	4,246	3,738
Other property, plant and equipment	2,760	2,326
Other intangible assets	926	672
Other assets	220	205
Deferred financing costs	131	141
Depreciation and amortization	$ 12,088	$ 10,438

Condensed Consolidated Statem59

Condensed Consolidated Statements of Cash Flows Supplemental Information (Details 2) - USD ($) $ in Thousands		3 Months Ended
		Mar. 31, 2017	Mar. 31, 2016
Write-downs, net of recoveries
Accounts receivable		$ 185	$ 126
Inventories		0	184
Film assets	[1]	3,416	0
Property, plant and equipment	[2]	409	329
Other intangible assets		0	9
Write-downs, net of recoveries		$ 4,010	$ 648
[1]	The Company reviewed the carrying value of certain documentary film assets as a result of lower than expected revenue being generated during the period and revised expectations for future revenues based on the latest information available. An impairment of $3.4 million was recorded based on the carrying value of these documentary films as compared to the related estimated future box office and revenues that would ultimately be generated by these films.
[2]	The Company recognized asset impairment charges of against property, plant and equipment after an assessment of the carrying value of certain assets in light of their future expected cash flows.

Condensed Consolidated Statem60

Condensed Consolidated Statements of Cash Flows Supplemental Information (Details Textual) - USD ($) $ in Thousands		3 Months Ended
		Mar. 31, 2017	Mar. 31, 2016
Asset Impairment Charges [Abstract]
Impairment on certain documentary film assets as a result of lower than expected revenue being generated during the period and revised expectations for future revenues based on the latest information available	[1]	$ 3,416	$ 0
[1]	The Company reviewed the carrying value of certain documentary film assets as a result of lower than expected revenue being generated during the period and revised expectations for future revenues based on the latest information available. An impairment of $3.4 million was recorded based on the carrying value of these documentary films as compared to the related estimated future box office and revenues that would ultimately be generated by these films.

Income Taxes (Details Textual)

Income Taxes (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016
Deferred Tax Assets
Change in Company's estimates of the recoverability of its deferred tax assets	$ 0
Deferred income tax asset after valuation allowance	29,500		$ 20,800
Deferred income tax asset before valuation allowance	29,700		21,000
Valuation allowance	200		$ 200
Provision for income taxes	114	$ 4,608
Recovery for windfall tax benefits	(300)
Tax provision related to the portion of losses applicable to non-controlling interests in the Company's Film Fund	600
Impact on accumulated deficit due to adoption of ASU 2016-16	8,314
Impact on other assets due to adoption of ASU 2016-16	(14,800)
Impact on deferred taxes due to adoption of ASU 2016-16	7,900
Impact on accrued and other liabilities due to adoption of ASU 2016-16	$ 1,400
Deferred tax asset reclass due to adoption of ASU 2016-09		$ 900

Capital Stock (Details 2)

Capital Stock (Details 2) - $ / shares	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Option activity under the Stock Option Plan and the IMAX LTIP
Options outstanding, end of period	5,268,603
Employee Stock Option [Member]
Option activity under the Stock Option Plan and the IMAX LTIP
Granted	679,030	323,925
Granted, weighted average exercise price per share	$ 32.16	$ 31.85
Exercised	(584,589)	(43,750)
Exercised, weighted average exercise price per share	$ 22.38	$ 16.91
Forfeited	(16,380)	(2,042)
Forfeited, weighted average exercise price per share	$ 31.69	$ 31.85
Options outstanding, end of period	5,268,603	5,083,377
Options outstanding, weighted average exercise price per share, end of period	$ 29.49	$ 27.42
Options exercisable, end of period	3,945,034	3,507,573
Options exercisable, weighted average exercise price per share, end of period	$ 28.68	$ 26.52

Capital Stock (Details 3)

Capital Stock (Details 3) - Restricted Share Units (RSUs) [Member] - $ / shares	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Resticted Share Units activity under the IMAX LTIP
Granted	373,540	351,584
Granted, weighted average grant date fair value per share	$ 32.45	$ 31.85
Vested and settled	(201,793)	(190,298)
Vested and settled, weighted average grant date fair value per share	$ 31.25	$ 29.47
Forfeited	(20,506)	(3,092)
Forfeited, weighted average grant date fair value per share	$ 32.31	$ 32.43
RSUs outstanding, end of period	1,275,421	1,131,831
RSUs outstanding, weighted average grant date fair value per share, end of period	$ 33.13	$ 32.61

Capital Stock (Details 4)

Capital Stock (Details 4) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Jan. 01, 2017	Dec. 31, 2016	Jan. 01, 2016
Net income applicable to common shareholders	$ 75	$ 11,302
Weighted average number of common shares:
Issued and outstanding, beginning of period	66,573,078		66,159,902	66,159,902	69,673,244
Weighted average number of shares issued (repurchased) during the period	202,826	(294,269)
Weighted average number of shares used in computing basic income per share	66,362,728	69,378,975
Assumed exercise of stock options and RSUs, net of shares assumed repurchased	817,104	740,951
Weighted average number of shares used in computing diluted income per share	67,179,832	70,119,926

Capital Stock (Details 5)

Capital Stock (Details 5) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Movement of Shareholders Equity
Balance as at December 31, 2016	$ 562,012
Net income attributable to common shareholders	75	$ 11,302
Retrospective adjustment related to intra-entity transfers (notes 2 and 11)	(8,314)
Adjustment to capital stock for cash received from issuance of common shares	13,082
Adjustment to capital stock for issuance of common shares for vested RSUs	273
Adjustment to capital stock for fair value of stock options exercised at the grant date	3,270
Adjustment to capital stock for share held in treasury	1,160
Adjustment to other equity for employee stock options granted	1,596
Adjustment to other equity for non-employee stock options granted and vested	17
Adjustment to other equity for fair value of stock options exercised at the grant date	(3,270)
Adjustment to other equity for RSUs granted	3,554
Adjustment to other equity for RSUs vested	(6,506)
Adjustment to other equity for stock exercised from treasury shares	(7,025)
Adjustment to accumulated other comprehensive loss for unrealized net gain from cash flow hedging instruments	313
Adjustment to accumulated other comprehensive loss for the realization of cash flow hedging net loss upon settlement	285
Adjustment to accumulated other comprehensive loss for foreign currency translation adjustments	312
Adjustment to accumulated other comprehensive loss for tax effect of movement in other comprehensive income	(157)
Balance as at March 31, 2017	$ 560,677

Capital Stock (Details Textual)

Capital Stock (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016	Dec. 31, 2014	Jan. 01, 2017	Jun. 06, 2016	Apr. 20, 2016	Jan. 01, 2016	Jun. 16, 2014
Capital Stock (Textuals) [Abstract]
Share-based compensation costs recorded for the period	$ 5,264	$ 5,900
Reserved common shares for future issuance	11,226,190		12,012,572
Options outstanding	5,268,603
Antidilutive shares issuable upon exercise of stock options and restricted share units	1,785,013	3,245,033
Details of the share repurchase program		On April 20, 2016 to increase the aggregate purchase allowance to $200.0 million.		On June 16, 2014, the Company’s board of directors approved a new $150.0 million share repurchase program for shares of the Company’s common stock, which program was amended on April 20, 2016 to increase the aggregate purchase allowance to $200.0 million. Purchases under the program commenced during the third quarter of 2014, and the program expires on June 30, 2017. The repurchases may be made either in the open market or through private transactions, subject to market conditions, applicable legal requirements and other relevant factors. The Company has no obligation to repurchase shares and the share repurchase program may be suspended or discontinued by the Company at any time.
Stock Repurchase Program, Authorized Amount							$ 200,000		$ 150,000
Stock Repurchase Program Expiration Date	Jun. 30, 2017
Stock Repurchased And Retired During Period, Shares	0	1,446,418
Stock Acquired, Average Cost per Share		$ 30.82
Payments For Repurchase Of Common Stock	$ 0	$ 44,618
Number of treasury shares held in trust for future settlement of share based awards	23,706		64,565
Value of treasury shares held in trust for future settlement of share based awards	$ 779		$ 1,939
Remaining available amount under share repurchase plan	46,300
Employee Stock Option [Member]
Capital Stock (Textuals) [Abstract]
Share-based compensation costs recorded for the period	1,350	2,400
Tax benefits realized stock options	$ 400	$ 1,300
Options exercisable	3,945,034	3,507,573
Options outstanding	5,268,603	5,083,377			5,190,542			4,805,244
Options outstanding, weighted average exercise price	$ 29.49	$ 27.42			$ 28.35			$ 27.03
Granted	679,030	323,925
Weighted average fair value of options granted	$ 9.08	$ 8.55
Options exercisable intrinsic value	$ 21,268
Cancelled	0	0
Weighted average remaining contractual life of exercisable option	4 years 7 months 6 days
Intrinsic value of options exercised	$ 6,000	$ 600
Options common shares were vested and exercisable	3,945,034
Options exercisable, weighted average exercise price per share, end of period	$ 28.68	$ 26.52
Antidilutive shares issuable upon exercise of stock options and restricted share units	1,613,340	2,630,005
Number of treasury shares held in trust for future settlement of share based awards	23,706		66,093
Weighted average exercise price of options forfeited	$ 31.69	$ 31.85
Options Non Employees [Member]
Capital Stock (Textuals) [Abstract]
Share-based compensation costs recorded for the period	less than	less than
Share-based compensation costs recorded for the period	$ 100	$ (100)
Options exercisable	17,000	26,325
Options outstanding	17,000	38,750
Options outstanding, weighted average exercise price	$ 29.64	$ 26.79
Granted	0	0
Amount for stock options or rights included in accrued liabilities			less than
Amount for stock options or rights included in accrued liabilities	$ 0		$ 100
Intrinsic value of options exercised	$ 100	$ 100
Options exercisable, weighted average exercise price per share, end of period	$ 29.64	$ 26.99
Employee Stock Option China Incentive Plan [Member]
Capital Stock (Textuals) [Abstract]
Share-based compensation costs recorded for the period	$ 200	$ 200
CSSBP [Member]
Capital Stock (Textuals) [Abstract]
Share-based compensation costs recorded for the period	100	100
Amount for stock options or rights included in accrued liabilities	400		$ 300
China RSU [Member]
Capital Stock (Textuals) [Abstract]
Share-based compensation costs recorded for the period	$ 100	$ 0
Restricted Share Units (RSUs) [Member]
Capital Stock (Textuals) [Abstract]
Number of RSUs outstanding	1,275,421	1,131,831			1,124,180			973,637
Share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period	373,540	351,584
RSUs outstanding, Weighted Average Grant Date Fair Value per Share	$ 33.13	$ 32.61			$ 33.01			$ 32.27
Antidilutive shares issuable upon exercise of stock options and restricted share units	171,673	615,028
Share-based compensation costs, not yet recognized, period for recognition	2 years 7 months 6 days	2 years 8 months 12 days
Share-based compensation costs, not yet recognized	$ 37,062	$ 32,000
Tax benefits realized	$ 1,900	$ 1,900
Restricted Stock Unit Contingent Right	1
Restricted Stock Unit Economic Equivalent	1
Common shares issued in connection with vested RSUs	201,793	190,298
Common shares issued from treasury in connection with vested RSUs	7,127	5,563
Common shares purchased in open market by trustee in connection with RSUs	190,084	181,227
Shares withheld for tax withholding	4,582	3,508
RSUs that may vest on shorter schedule	260,274					300,000
RSUs issued from carve-out	0		39,726
Restricted Share Units (RSUs) [Member] | Employee [Member]
Capital Stock (Textuals) [Abstract]
Share-based compensation costs recorded for the period	$ 3,400	$ 3,100
Common shares purchased in open market by trustee in connection with RSUs	368,624	181,277
Weighted average price of common shares purchased in open market by trustee in connection with RSUs	$ 32.38	$ 32.28
Restricted Share Units (RSUs) [Member] | Non Employee [Member]
Capital Stock (Textuals) [Abstract]
Share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period	0	0
Maximum [Member] | Restricted Share Units (RSUs) [Member]
Capital Stock (Textuals) [Abstract]
Stock based awards vesting period	4 years	4 years
Minimum [Member] | Restricted Share Units (RSUs) [Member]
Capital Stock (Textuals) [Abstract]
Stock based awards vesting period	1 year	0 years

Segmented Information (Details

Segmented Information (Details 1) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Geographical Information
Revenues, total	$ 68,657	$ 92,128
United States [Member]
Geographical Information
Revenues, total	25,198	35,544
Canada [Member]
Geographical Information
Revenues, total	3,282	7,077
Greater China [Member]
Geographical Information
Revenues, total	18,590	24,939
Asia (excluding Greater China) [Member]
Geographical Information
Revenues, total	8,429	5,559
Western Europe [Member]
Geographical Information
Revenues, total	5,813	11,486
Russia & the CIS [Member]
Geographical Information
Revenues, total	3,183	1,692
Latin America [Member]
Geographical Information
Revenues, total	1,654	3,527
Rest of the World [Member]
Geographical Information
Revenues, total	$ 2,508	$ 2,304

Segmented Information (Detail68

Segmented Information (Details Textual) $ in Millions	3 Months Ended		12 Months Ended
	Mar. 31, 2017USD ($)Segments	Mar. 31, 2016USD ($)	Dec. 31, 2016Segments
Segment Reporting (Textuals) [Abstract]
Number of Reportable Segments | Segments	8
Percentage of total revenues represented by largest customer	17.2%	16%
Marketing and commission costs	$ 0.4	$ 0.7
Disclosure on Geographic Areas, Description of Revenue from External Customers	No single country in the Rest of the World, Western Europe, Latin America and Asia (excluding Greater China) classifications comprises more than 10% of the total revenue.
Description of products and services from which each reportable segment derives its revenues	The Company’s reportable segments are now under four primary groups identified by nature of product sold or service provided: (1) Network Business, representing variable revenue generated by box-office results and which includes the reportable segment of IMAX DMR and contingent rent from the joint revenue sharing arrangements and IMAX systems segments; (2) Theater Business, representing revenue generated by the sale and installation of theater systems and maintenance services, primarily related to the IMAX Systems and Theater System Maintenance reportable segments, and also includes fixed hybrid revenues and upfront installation costs from the joint revenue sharing arrangements segment and after-market sales of projection system parts and 3D glasses from the other segment; (3) New Business, which includes content licensing and distribution fees associated with our original content investments, virtual reality initiatives, IMAX Home Entertainment, and other business initiatives that are in the development and/or start-up phase, and (4) Other; which includes the film post-production and distribution segments and certain IMAX theaters that the Company owns and operates, camera rentals and other miscellaneous items from the other segment.
Description of the basis of accounting for transactions between reportable segments	The accounting policies of the segments are the same as those described in note 2 to the audited consolidated financial statements included in the Company’s 2016 Form 10-K. In addition, refer to Item 2 of the Company’s Form 10-Q for additional information regarding the four primary groups mentioned above. Transactions between the IMAX DMR segment and the film post-production segment are valued at exchange value. Inter-segment profits are eliminated upon consolidation.
Number of Primary Groups | Segments	4		2
IMAX DMR [Member]
Segment Reporting (Textuals) [Abstract]
Marketing costs (recovery)	$ 2.6	2.3
Joint revenue sharing arrangements [Member]
Segment Reporting (Textuals) [Abstract]
Advertising, marketing and commission costs (recovery)	0.4	0.1
IMAX Systems [Member]
Segment Reporting (Textuals) [Abstract]
Advertising, marketing and commission costs (recovery)	0.4	0.5
Film distribution [Member]
Segment Reporting (Textuals) [Abstract]
Marketing costs (recovery)	$ (0.2)	$ 0.7

Employees Pension and Postret69

Employees Pension and Postretirement Benefits (Details 1) $ in Thousands	Mar. 31, 2017USD ($)
SERP Benefits [Member]
Schedule of expected benefit payments
2017 (nine months remaining)	$ 0
2,018	0
2,019	0
2,020	21,115
2,021	0
Thereafter	0
Total expected future benefit payment	21,115
Postretirement Benefits Executives [Member]
Schedule of expected benefit payments
2017 (nine months remaining)	21
2,018	24
2,019	26
2,020	33
2,021	36
Thereafter	514
Total expected future benefit payment	654
Postretirement Benefits Canadian Employees [Member]
Schedule of expected benefit payments
2017 (nine months remaining)	92
2,018	99
2,019	105
2,020	108
2,021	110
Thereafter	1,244
Total expected future benefit payment	$ 1,758

Employees Pension and Postret70

Employees Pension and Postretirement Benefits (Details Textuals) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016	Sep. 01, 2016	Dec. 31, 2015
SERP Benefits [Member]
Pension and Other Postretirement Benefit Expense (Textuals) [Abstract]
Accumulated benefit obligation for the SERP	$ 19,700		$ 19,600
Benefit Obligation	19,687		19,580		$ 19,478
Companies contribution and expenses	0
Expected interest costs in the remainder of the year	$ 300
SERP assumptions	The SERP assumptions are that Mr. Gelfond will receive a lump sum payment six months after retirement at the end of the current term of his employment agreement (December 31, 2019), although Mr. Gelfond has not informed the Company that he intends to retire at that time.
Defined Contribution Plan [Member]
Pension and Other Postretirement Benefit Expense (Textuals) [Abstract]
Description Of Defined Contribution Pension And Other Postretirement Plans	The Company also maintains defined contribution pension plans for its employees, including its executive officers. The Company makes contributions to these plans on behalf of employees in an amount up to 5% of their base salary subject to certain prescribed maximums.
Maximum percentage of base salary contributed to Defined Contribution Pension Plan by Company	5.00%
Postretirement Benefits Executives [Member]
Pension and Other Postretirement Benefit Expense (Textuals) [Abstract]
Benefit Obligation	$ 654		647
Maximum amount of Postretirement benefit expensed	less than	less than
Maximum amount of Postretirement benefit expensed	$ 100	$ 100
Postretirement Benefits Canadian Employees [Member]
Pension and Other Postretirement Benefit Expense (Textuals) [Abstract]
Benefit Obligation	$ 1,758		1,745
Maximum amount of Postretirement benefit expensed	less than	less than
Maximum amount of Postretirement benefit expensed	$ 100	$ 100
Canadian Plan [Member]
Pension and Other Postretirement Benefit Expense (Textuals) [Abstract]
Companies contribution and expenses	329	401
Us Internal Revenue Code [Member]
Pension and Other Postretirement Benefit Expense (Textuals) [Abstract]
Companies contribution and expenses	$ 234	221
Deferred Compensation Plan [Member]
Pension and Other Postretirement Benefit Expense (Textuals) [Abstract]
Deferred compensation plan description	In September 2016, the Company entered into a new employment agreement with Greg Foster, CEO of IMAX Entertainment, which provides for an employment term from July 2, 2016 through July 2, 2019. Under the agreement, the Company agreed to create a deferred compensation plan (the “Retirement Plan”) covering Mr. Foster, and to make a total contribution of $3.2 million over the three-year employment term. The Retirement Plan is subject to a vesting schedule based on continued employment with the Company, such that 25% will vest July 2019; 50% will vest July 2022; 75% will vest July 2025; and will be 100% vested in July 2027.
Requisite employment term	2 years 3 months 2 days
Total contibution obligation over employment term				$ 3,200
Unfunded benefit obligation recorded	$ 800		$ 500
Compensation expense recognized	$ 300	$ 0

Financial Instruments (Details

Financial Instruments (Details 2) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Recorded investment in financing receivables by credit quality indicator
Minimum Lease Payments	$ 8,480	$ 8,756
Financed Sales Receivables	113,176	114,535
Total	121,656	123,291
In Good Standing [Member]
Recorded investment in financing receivables by credit quality indicator
Minimum Lease Payments	7,465	7,741
Financed Sales Receivables	110,249	111,568
Total	117,714	119,309
Credit Watch Member [Member]
Recorded investment in financing receivables by credit quality indicator
Minimum Lease Payments	0	0
Financed Sales Receivables	1,683	1,514
Total	1,683	1,514
Pre-Approved Transactions [Member]
Recorded investment in financing receivables by credit quality indicator
Minimum Lease Payments	0	0
Financed Sales Receivables	633	842
Total	633	842
Transactions Suspended [Member]
Recorded investment in financing receivables by credit quality indicator
Minimum Lease Payments	1,015	1,015
Financed Sales Receivables	611	611
Total	$ 1,626	$ 1,626

Financial Instruments (Detail72

Financial Instruments (Details 3) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Investment In Financing Receivables On Nonaccrual Status
Net investment in leases recorded investment	$ 1,015	$ 1,015
Net investment in leases related allowance	(672)	(672)
Net financed sales receivables recorded investment	611	611
Net financed sales receivables related allowance	(494)	(494)
Total recorded investment	1,626	1,626
Total related allowance	$ (1,166)	$ (1,166)

Financial Instruments (Detail73

Financial Instruments (Details 4) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016	Mar. 31, 2016	Dec. 31, 2015
Financing Receivable, Recorded Investment, Past Due [Line Items]
Billed Financing Receivables	$ 8,040	$ 7,453
Related Unbilled Recorded Investment	113,617	115,838
Total Recorded Investment	121,656	123,291
Related Allowances	(1,166)	(1,166)
Recorded Investment Net of Allowances	120,490	122,125
Financing Receivables Accrued and Current
Financing Receivable, Recorded Investment, Past Due [Line Items]
Billed Financing Receivables	1,925	2,421
Financing Receivables 30 to 89 Days Past Due [Member]
Financing Receivable, Recorded Investment, Past Due [Line Items]
Billed Financing Receivables	2,473	1,883
Financing Receivables Equal To Greater Than 90 Days Past Due [Member]
Financing Receivable, Recorded Investment, Past Due [Line Items]
Billed Financing Receivables	3,642	3,149
Net Investment in Leases [Member]
Financing Receivable, Recorded Investment, Past Due [Line Items]
Billed Financing Receivables	898	968
Related Unbilled Recorded Investment	7,582	7,788
Total Recorded Investment	8,480	8,756
Related Allowances	(672)	(672)	$ (672)	$ (672)
Recorded Investment Net of Allowances	7,808	8,084
Net Investment in Leases [Member] | Financing Receivables Accrued and Current
Financing Receivable, Recorded Investment, Past Due [Line Items]
Billed Financing Receivables	41	28
Net Investment in Leases [Member] | Financing Receivables 30 to 89 Days Past Due [Member]
Financing Receivable, Recorded Investment, Past Due [Line Items]
Billed Financing Receivables	94	159
Net Investment in Leases [Member] | Financing Receivables Equal To Greater Than 90 Days Past Due [Member]
Financing Receivable, Recorded Investment, Past Due [Line Items]
Billed Financing Receivables	763	781
Net Financed Sales Receivables [Member]
Financing Receivable, Recorded Investment, Past Due [Line Items]
Billed Financing Receivables	7,142	6,485
Related Unbilled Recorded Investment	106,035	108,050
Total Recorded Investment	113,176	114,535
Related Allowances	(494)	(494)	$ (643)	$ (568)
Recorded Investment Net of Allowances	112,682	114,041
Net Financed Sales Receivables [Member] | Financing Receivables Accrued and Current
Financing Receivable, Recorded Investment, Past Due [Line Items]
Billed Financing Receivables	1,884	2,393
Net Financed Sales Receivables [Member] | Financing Receivables 30 to 89 Days Past Due [Member]
Financing Receivable, Recorded Investment, Past Due [Line Items]
Billed Financing Receivables	2,379	1,724
Net Financed Sales Receivables [Member] | Financing Receivables Equal To Greater Than 90 Days Past Due [Member]
Financing Receivable, Recorded Investment, Past Due [Line Items]
Billed Financing Receivables	2,879	2,368
Financing Receivables Continue To Accrue Finance Income [Member]
Financing Receivable, Recorded Investment, Past Due [Line Items]
Billed Financing Receivables	3,786	3,070
Related Unbilled Recorded Investment	28,113	21,793
Related Allowances	0	0
Recorded Investment Net of Allowances	31,899	24,863
Financing Receivables Continue To Accrue Finance Income [Member] | Financing Receivables Accrued and Current
Financing Receivable, Recorded Investment, Past Due [Line Items]
Billed Financing Receivables	184	284
Financing Receivables Continue To Accrue Finance Income [Member] | Financing Receivables 30 to 89 Days Past Due [Member]
Financing Receivable, Recorded Investment, Past Due [Line Items]
Billed Financing Receivables	1,029	688
Financing Receivables Continue To Accrue Finance Income [Member] | Financing Receivables Equal To Greater Than 90 Days Past Due [Member]
Financing Receivable, Recorded Investment, Past Due [Line Items]
Billed Financing Receivables	2,573	2,098
Financing Receivables Continue To Accrue Finance Income [Member] | Net Investment in Leases [Member]
Financing Receivable, Recorded Investment, Past Due [Line Items]
Billed Financing Receivables	392	298
Related Unbilled Recorded Investment	2,237	1,646
Related Allowances	0	0
Recorded Investment Net of Allowances	2,629	1,944
Financing Receivables Continue To Accrue Finance Income [Member] | Net Investment in Leases [Member] | Financing Receivables Accrued and Current
Financing Receivable, Recorded Investment, Past Due [Line Items]
Billed Financing Receivables	38	0
Financing Receivables Continue To Accrue Finance Income [Member] | Net Investment in Leases [Member] | Financing Receivables 30 to 89 Days Past Due [Member]
Financing Receivable, Recorded Investment, Past Due [Line Items]
Billed Financing Receivables	61	54
Financing Receivables Continue To Accrue Finance Income [Member] | Net Investment in Leases [Member] | Financing Receivables Equal To Greater Than 90 Days Past Due [Member]
Financing Receivable, Recorded Investment, Past Due [Line Items]
Billed Financing Receivables	293	244
Financing Receivables Continue To Accrue Finance Income [Member] | Net Financed Sales Receivables [Member]
Financing Receivable, Recorded Investment, Past Due [Line Items]
Billed Financing Receivables	3,394	2,772
Related Unbilled Recorded Investment	25,876	20,147
Related Allowances	0	0
Recorded Investment Net of Allowances	29,270	22,919
Financing Receivables Continue To Accrue Finance Income [Member] | Net Financed Sales Receivables [Member] | Financing Receivables Accrued and Current
Financing Receivable, Recorded Investment, Past Due [Line Items]
Billed Financing Receivables	146	284
Financing Receivables Continue To Accrue Finance Income [Member] | Net Financed Sales Receivables [Member] | Financing Receivables 30 to 89 Days Past Due [Member]
Financing Receivable, Recorded Investment, Past Due [Line Items]
Billed Financing Receivables	968	634
Financing Receivables Continue To Accrue Finance Income [Member] | Net Financed Sales Receivables [Member] | Financing Receivables Equal To Greater Than 90 Days Past Due [Member]
Financing Receivable, Recorded Investment, Past Due [Line Items]
Billed Financing Receivables	$ 2,280	$ 1,854

Financial Instruments (Detail74

Financial Instruments (Details 5) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Financing Receivable, Impaired [Line Items]
Recorded Investment	$ 525	$ 748
Unpaid Principal	75	414
Related Allowance	(494)	(643)
Average Recorded Investment	525	748
Interest Income Recognized	0	0
Net Financed Sales Receivables [Member]
Financing Receivable, Impaired [Line Items]
Impaired Financing Receivable with Related Allowance, Recorded Investment	525	748
Impaired Financing Receivable With Related Allowance, Unpaid Principal	75	414
Impaired Financing Receivable With Related Allowance, Average Recorded Investment	525	748
Impaired Financing Receivable With Related Allowance, Interest Income Recognized	0	0
Impaired Financing Receivable With No Related Allowance, Recorded Investment	0	0
Impaired Financing Receivable With No Related Allowance, Unpaid Principal	0	0
Impaired Financing Receivable With No Related Allowance, Average Recorded Investment	0	0
Impaired Financing Receivable With No Related Allowance, Interest Income Recognized	0	0
Related Allowance	$ (494)	$ (643)

Financial Instruments (Detail75

Financial Instruments (Details 6) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Allowance for credit losses:
Beginning balance	$ 1,166
Ending balance	1,166
Net Investment in Leases [Member]
Allowance for credit losses:
Beginning balance	672	$ 672
Charge-offs	0	0
Recoveries	0	0
Provision	0	0
Ending balance	672	672
Ending balance: individually evaluated for impairment	672	672
Financing receivables:
Ending balance: individually evaluated for impairment	8,480	10,577
Net Financed Sales Receivables [Member]
Allowance for credit losses:
Beginning balance	494	568
Charge-offs	0	0
Recoveries	0	0
Provision	0	75
Ending balance	494	643
Ending balance: individually evaluated for impairment	494	643
Financing receivables:
Ending balance: individually evaluated for impairment	$ 113,176	$ 110,387

Financial Instruments (Detail76

Financial Instruments (Details 7) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Foreign Exchange Contract [Member] | Designated as Hedging Instrument [Member]
Derivatives Fair Value [Line Items]
Foreign exchange contracts - Forwards	$ 39,802	$ 37,825

Financial Instruments (Detail77

Financial Instruments (Details 8) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Fair value of foreign exchange contracts
Foreign exchange contracts - designated forwards	$ 302	$ (296)
Other Assets [Member] | Designated as Hedging Instrument [Member]
Fair value of foreign exchange contracts
Derivative Asset, Fair Value	604	480
Accrued and other liabilities [Member] | Designated as Hedging Instrument [Member]
Fair value of foreign exchange contracts
Derivative Liability, Fair Value	$ (302)	$ (776)

Financial Instruments (Detail78

Financial Instruments (Details 9) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Derivatives in Foreign Currency Hedging relationships
Derivative Gain Recognized in OCI (Effective Portion)	$ 313	$ 2,207
Location of Derivative Loss Reclassified from AOCI into Income (Effective Portion)	(285)	(1,277)
Derivative Loss Recognized In and Out of OCI (Effective Portion)	(47)	0
Selling, general and administrative expenses [Member]
Derivatives in Foreign Currency Hedging relationships
Location of Derivative Loss Reclassified from AOCI into Income (Effective Portion)	(285)	(1,277)
Fair Value Hedging [Member]
Derivatives in Foreign Currency Hedging relationships
Derivative Gain Recognized in OCI (Effective Portion)	$ 313	$ 2,207

Financial Instruments (Detail79

Financial Instruments (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016
Financial Instruments (Textuals) [Abstract]
Transfers into/out of Level 3	$ 0	$ 0
Financing receivables indications of theaters with potential collection concerns	60-89 days
Financing receivables indications of theaters to review and assess	Once a theater’s aging exceeds 90 days, the Company’s policy is to review and assess collectibility on the theat
Financing receivables indications of theaters with potential impairment	Over 90 days past due is used by the Company as an indicator of potential impairment as invoices up to 90 days outstanding could be considered reasonable due to the time required for dispute resolution or for the provision of further information or supporting documentation to the customer
Estimated gain to be reclassified to earnings within the next twelve months	$ 400
Financial Instruments Additional (Textuals) [Abstract]
Total carrying value of investments in new business ventures	3,000		$ 2,000
Convertible loan receivable			1,000
Convertible loan effective interest rate		5.00%
Convertible loan receivable due date		Sep. 26, 2019
Schedule of Available For Sale Securities [Line Items]
Available-for-sale Securities, Debt Securities	1,500
Investment classified as available-for-sale - fair value	0		0
Variable Interest Entity, Not Primary Beneficiary [Member]
Financial Instruments Additional (Textuals) [Abstract]
Carrying value of investments accounted for under the equity method of accounting	0		0
Equity method investment, difference between carrying amount and underlying equity	700
Variable Interest Entity, Not Primary Beneficiary [Member] | Equity Accounted Investment [Member]
Financial Instruments Additional (Textuals) [Abstract]
Gross revenues of investment new business ventures	200	$ 400
Cost of revenue of investment new business ventures	900	2,200
Net loss on equity-accounted investments	700	$ 1,800
Other Debt Securities [Member]
Schedule of Available For Sale Securities [Line Items]
Investment classified as available-for-sale - cost	3,500
Investment classified as available-for-sale - fair value	1,000		0
Fixed Income Securities [Member]
Schedule of Available For Sale Securities [Line Items]
Investment classified as available-for-sale - cost	$ 1,000		$ 1,000

Non-Controlling Interests (De80

Non-Controlling Interests (Details Textuals) $ in Thousands	Feb. 10, 2015USD ($)	Apr. 08, 2014USD ($)	Mar. 31, 2017USD ($)	Mar. 31, 2016USD ($)	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)yrFilm
Redeemable Noncontrolling Interest [Line Items]
Investment in film assets			$ (3,334)	$ (3,919)
IMAX China Noncontrolling Interest
Redeemable Noncontrolling Interest [Line Items]
Non-controlling interest description		On April 8, 2014, the Company announced the sale and issuance of 20.0% of the shares in IMAX China to entities owned and controlled by CMC Capital Partners ("CMC"), an investment fund focused on media and entertainment, and FountainVest Partners ("FountainVest"), a China-focused private equity firm.
Minority Interest Ownership Percentage By Company			68.20%
Minority Interest Ownership Percentage By Noncontrolling Owners		20.00%
Dividends paid					$ 9,500
IMAX China Noncontrolling Interest | Class C Shares [Member]
Redeemable Noncontrolling Interest [Line Items]
Aggregate subscription price	$ 40,000	$ 40,000
Other Noncontrolling Interest [Member]
Redeemable Noncontrolling Interest [Line Items]
Non-controlling interest description						In 2014, the Company announced the creation of the Film Fund to co-finance a portfolio of 10 original large-format films. The Film Fund, which is intended to be capitalized with up to $50.0 million, will finance an ongoing supply of original films that the Company believes will be more exciting and compelling than traditional documentaries. The initial investment in the Film Fund was committed to by a third party in the amount of $25.0 million, with the possibility of contributing additional funds. The Company agreed to contribute $9.0 million to the Film Fund over five years starting in 2014 and sees the Film Fund as a self-perpetuating vehicle designed to generate a continuous, steady flow of high-quality documentary content.
Number Of Expected Original Films | Film						10
Film Fund Expected Capital Contribution						$ 50,000
Investment in film assets			$ 13,400
Other Noncontrolling Interest [Member] | Third Party [Member]
Redeemable Noncontrolling Interest [Line Items]
Film Fund commitment amount						25,000
Other Noncontrolling Interest [Member] | IMAX [Member]
Redeemable Noncontrolling Interest [Line Items]
Film Fund commitment amount						$ 9,000
Contribution Period | yr						5